

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/207339 A1

- (51) International Patent Classification:
C12N 15/113 (2010.01) A61P 35/00 (2006.01)
- (21) International Application Number:
PCT/US2021/026147
- (22) International Filing Date:
07 April 2021 (07.04.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
16/842,404 07 April 2020 (07.04.2020) US
- (71) Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 109 Church Street, Chapel Hill, North Carolina 27516 (US).
- (72) Inventors: PECOT, Chad; 37 Linda Lee Circle, Pittsboro, North Carolina 27312 (US). AZAM, Salma H.; 503 Hollowridge Court, Cary, North Carolina 27519 (US).
- (74) Agent: SCHWARTZMAN, Robert, A.; MYERS BIGEL, P.A., PO Box 37428, Raleigh, North Carolina 27627 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS

	KRAS GENE:	CODON		SEQ ID NO:
		12	13	
WILD-TYPE	ACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGATACAG	GGT	GGC	40
G12C MUT	ACTGAATATAAACTTGTGGTAGTTGGAGCTTGTGGCGTAGGCAAGAGTGCCTTGACGATACAG	TGT	GGC	41
G12D MUT	ACTGAATATAAACTTGTGGTAGTTGGAGCTGATGGCGTAGGCAAGAGTGCCTTGACGATACAG	GAT	GGC	42
G12V MUT	ACTGAATATAAACTTGTGGTAGTTGGAGCTGTTGGCGTAGGCAAGAGTGCCTTGACGATACAG	GTT	GGC	43
G13D MUT	ACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGACGTAGGCAAGAGTGCCTTGACGATACAG	GGT	GAC	44
siRNA:				
G12C	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUGUGGCGUAGGCAAGAGUGCCUUGACGAUACAG	UUG	GCG	45
G12D	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGGCGUAGGCAAGAGUGCCUUGACGAUACAG	UAU	GCG	46
12CD13D_1	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGACUAGGCAAGAGUGCCUUGACGAUACAG	UAU	GAC	47
12CD13D_2	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGACUAGGCAAGAGUGCCUUGACGAUACAG	UAU	GAC	47
12CD13D_3	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGACUAGGCAAGAGUGCCUUGACGAUACAG	UAU	GAC	47
12CD13D_4	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGACUAGGCAAGAGUGCCUUGACGAUACAG	UAU	GAC	47
12CV13D_1	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGACUAGGCAAGAGUGCCUUGACGAUACAG	UUU	GAC	48
12CV13D_2	ACUGAAUAUAAACUUGUGGUAGUUGGAGCUUUAUGACUAGGCAAGAGUGCCUUGACGAUACAG	UUU	GAC	48
CONTROL siRNA:				
NC	UUCUCCGAACGUGUCACGU			49
SEQ2	GUCUCUUGGAUUAUUCUGA			50
SEQ3	CAGCUAAUUCAGAAUCAUU			51

FIG. 1

(57) Abstract: The invention relates to the inhibition of expression of mutant KRAS sequences using RNA interference, antisense oligonucleotides, and chemically-modified oligonucleotides.

WO 2021/207339 A1

METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS

STATEMENT OF PRIORITY

[0001] This application claims the benefit of US. Application No. 16/842,404, filed April 7, 2020, the entire contents of which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

[0002] The invention relates to the inhibition of expression of mutant KRAS sequences using RNA interference, antisense oligonucleotides, and chemically-modified oligonucleotides.

BACKGROUND OF THE INVENTION

[0003] Since its discovery in 1982, the RAS family of genes has been characterized as an important class of proto-oncogenes (Cox *et al.*, *Nat. Rev. Drug Discov.* 13:828 (2014)). Through three decades of extensive research, mutational activation of certain RAS genes (KRAS, NRAS, and HRAS) has been implicated in nearly one-third of all cancers (Pecot *et al.*, *Mol. Cancer Ther.* 13:2876 (2014)). In particular, KRAS mutations are observed most frequently, both exclusively and in conjunction with the other RAS isoforms (Cox *et al.*, *Nat. Rev. Drug Discov.* 13:828 (2014)). Yet in spite of efforts to develop inhibitors for this highly prevalent mutation, no strong therapeutic candidates have emerged, thus earning the KRAS gene its reputation as an elusively “undruggable” target.

[0004] The RAS genes encode a family of small GTPases that act upon downstream effector proteins to promote cell survival, growth, and proliferation (Khosravi-Far *et al.*, *Cancer Metastasis Rev.* 13:67 (1994)). Proper function of the RAS proteins relies upon activation via a guanine nucleotide exchange factor (GEF) to its active, GTP-bound form as well as membrane association of the RAS-GTP complex, both of which have been proposed as targets for KRAS inhibition. However, due to low efficacy and target specificity of previously proposed therapeutic agents in directly inhibiting KRAS, current measures to target the KRAS pathway focus predominantly on inhibition of downstream effector proteins (Cox *et al.*, *Nat. Rev. Drug Discov.* 13:828 (2014)). Nevertheless, despite challenges in developing a small molecule to directly down-regulate gene activity, KRAS remains a therapeutically relevant target due to its prevalence as a driving mutation in human cancers.

[0005] Advances in RNA interference (RNAi) suggest its potential as an effective means of

knocking down KRAS expression. RNAi therapy uses the interaction of an exogenous small interfering RNA (siRNA) and endogenous enzymatic machinery, termed an RNA-induced silencing complex (RISC), to selectively silence specific genes at the mRNA level (Pecot *et al.*, *Nat. Rev. Cancer* 11:59 (2011)). A recent study has revealed the efficacy of RNAi as a well-tolerated therapy for inducing metastatic regression in human cancer patients (Taberero *et al.*, *Cancer Discov.* 3:406 (2013)). In addition, using nanoliposomes we have recently verified the efficacy of siRNA delivery for knockdown of human KRAS in various lung and colon cancer models, both *in vitro* and *in vivo* (Pecot *et al.*, *Mol. Cancer Ther.* 13:2876 (2014)).

[0006] However, there remains a lack of target-specificity for mutant KRAS over the wild-type (WT) allele. Despite the oncogenic properties of the mutant allele, WT KRAS is necessary for proper response to extra-cellular inputs that promote viability in non-cancerous cells (Khosravi-Far *et al.*, *Cancer Metastasis Rev.* 13:67 (1994)). As such, there is a need for inhibitors that target mutant KRAS while sparing WT KRAS.

[0007] Accordingly, the present invention overcomes the deficiencies in the art by providing compositions and methods using RNA interference for specific inhibition of mutant KRAS sequences.

SUMMARY OF THE INVENTION

[0008] The present invention is based on the identification of RNA molecules that inhibit expression of mutant KRAS sequences while sparing expression of WT KRAS. Accordingly, one aspect of the invention relates to a double stranded RNA molecule comprising an antisense strand and a sense strand, wherein the nucleotide sequence of the antisense strand is complementary to a region of the nucleotide sequence of a synthetic human KRAS gene that contains the missense mutations G12C, G12D, and G13D or the missense mutations G12C, G12V, and G13D, the region consisting essentially of about 18 to about 25 consecutive nucleotides; wherein the double stranded RNA molecule inhibits expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D and minimally inhibits expression of wild-type human KRAS.

[0009] Another aspect of the invention relates to a composition, *e.g.*, a pharmaceutical composition, comprising one or more of the RNA molecules of the invention.

[0010] A further aspect of the invention relates to a method of inhibiting expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D,

G12V, and G13D in a cell, the method comprising contacting the cell with the RNA molecule of the invention, thereby inhibiting expression of the mutant human KRAS gene in the cell.

[0011] An additional aspect of the invention relates to a method of treating cancer in a subject in need thereof, wherein the cancer comprises a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D, the method comprising delivering to the subject the RNA molecule of the invention, thereby treating cancer in the subject.

[0012] Another aspect of the invention relates to the use of the RNA molecules of the invention to inhibit expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D in a cell and to treat cancer in a subject in need thereof, wherein the cancer comprises a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D.

[0013] A further aspect of the invention relates to an antisense oligonucleotide targeted to a synthetic human KRAS mRNA that encodes the missense mutations G12C, G12D, and G13D, wherein the antisense oligonucleotide is 16-25 nucleotides in length and comprises the sequence TCTTGCCTACGTCATA (SEQ ID NO:114).

[0014] An additional aspect of the invention relates to an antisense oligonucleotide targeted to a naturally-occurring human KRAS mRNA encoding a mutation selected from G12C, G12D, G12V, and G13D, wherein the antisense oligonucleotide is 16-25 nucleotides in length and comprises a sequence selected from:

- a) TCTTGCCTACGCCACA (SEQ ID NO:117) targeted to a human KRAS mRNA encoding a G12C mutation;
- b) TCTTGCCTACGCCATC (SEQ ID NO:118) targeted to a human KRAS mRNA encoding a G12D mutation;
- c) TCTTGCCTACGCCAAC (SEQ ID NO:119) targeted to a human KRAS mRNA encoding a G12V mutation;
- d) TCTTGCCTACGTCACC (SEQ ID NO:120) targeted to a human KRAS mRNA encoding a G13D mutation; or
- e) a sequence at least 90% identical to any one of a) to d)

wherein the antisense oligonucleotide comprises at least one non-naturally occurring chemical modification.

[0015] Another aspect of the invention relates to a siRNA molecule targeted to a naturally-occurring human KRAS mRNA encoding a mutation selected from G12C, G12D, G12V, and

G13D, wherein the siRNA molecule comprises at least one chemical modification, and wherein the siRNA molecule comprises one of the following pairs of sequences:

sense strand of **SEQ ID NO:128** and antisense strand of **SEQ ID NO:129**;
sense strand of **SEQ ID NO:130** and antisense strand of **SEQ ID NO:131**;
sense strand of **SEQ ID NO:132** and antisense strand of **SEQ ID NO:133**;
sense strand of **SEQ ID NO:134** and antisense strand of **SEQ ID NO:135**;
sense strand of **SEQ ID NO:136** and antisense strand of **SEQ ID NO:137**;
sense strand of **SEQ ID NO:138** and antisense strand of **SEQ ID NO:139**;
sense strand of **SEQ ID NO:140** and antisense strand of **SEQ ID NO:141**;
sense strand of **SEQ ID NO:142** and antisense strand of **SEQ ID NO:143**;
sense strand of **SEQ ID NO:144** and antisense strand of **SEQ ID NO:145**;
sense strand of **SEQ ID NO:146** and antisense strand of **SEQ ID NO:147**;
sense strand of **SEQ ID NO:148** and antisense strand of **SEQ ID NO:149**;
sense strand of **SEQ ID NO:150** and antisense strand of **SEQ ID NO:151**;
sense strand of **SEQ ID NO:152** and antisense strand of **SEQ ID NO:153**;
sense strand of **SEQ ID NO:154** and antisense strand of **SEQ ID NO:155**;
sense strand of **SEQ ID NO:156** and antisense strand of **SEQ ID NO:157**; or
sense strand of **SEQ ID NO:158** and antisense strand of **SEQ ID NO:159**;

or a sequence at least 90% identical thereto.

[0016] An additional aspect of the invention relates to an siRNA molecule targeted to human KRAS mRNA, wherein the sense strand of the siRNA comprises the sequence of SEQ ID NO:50 or SEQ ID NO:51, and wherein the siRNA comprises at least one non-naturally occurring chemical modification.

[0017] Another aspect of the invention relates to a composition, *e.g.*, a pharmaceutical composition, comprising one or more of the antisense oligonucleotides or siRNAs molecules of the invention.

[0018] A further aspect of the invention relates to a method of inhibiting expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D in a cell, the method comprising contacting the cell with the antisense oligonucleotides or siRNAs molecules of the invention, thereby inhibiting expression of the mutant human KRAS gene in the cell.

[0019] An additional aspect of the invention relates to a method of treating cancer in a subject in need thereof, wherein the cancer comprises a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D, the

method comprising delivering to the subject the antisense oligonucleotides or siRNAs molecules of the invention, thereby treating cancer in the subject.

[0020] Another aspect of the invention relates to the use of the antisense oligonucleotides or siRNAs molecules of the invention to inhibit expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D in a cell and to treat cancer in a subject in need thereof, wherein the cancer comprises a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D.

[0021] These and other aspects of the invention are set forth in more detail in the description of the invention below.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 shows KRAS siRNA sequences (**SEQ ID NOS:40-51**). TMS siRNA sequences were designed to bind the G domain of the human KRAS gene at codons 12 and 13 and target three point mutations (each indicated with an asterisk). Underlining indicates the remaining base pairs targeted by the siRNA (sense). Sequences for G12C and G12D siRNAs were obtained from Fleming *et al.*, *Mol. Cancer Res.* 3:413 (2005). Positive control siRNAs (Seq2 and Seq3) were obtained from Pecot *et al.*, *Mol. Cancer Ther.* 13:2876 (2014) and targeted a downstream coding region of the KRAS mRNA.

[0023] Figures 2A-2B show KRAS expression levels with mutant-specific (MS) and control siRNAs. NIH 3T3 cells infected with human WT, G12C, G12D, G12V, or G13D KRAS were reverse transfected with either (A) MS siRNA sequences (12CD13D_1, 12CD13D_2, 12CD13D_3, 12CD13D_4, 12CV13D_1, and 12CV13D_2) or (B) control mutant-specific siRNA or non-specific sequences.

[0024] Figure 3 shows the testing of custom KRAS siRNA sequences 12CD13D_1 and 12CD13D_4 in a KRAS G12D mutant lung cancer cell line.

[0025] Figure 4 shows the library of siRNA sequences (**SEQ ID NOS:45-51**) used for testing all possible siRNA sequence permutations between the custom siRNA sequences.

[0026] Figure 5 shows the relative expression of wild-type and mutant KRAS mRNAs in 3T3 cells.

[0027] Figure 6 shows a schematic of the antisense oligonucleotide screen against the synthetic KRAS gene (**SEQ ID NOS:52 and 53**).

[0028] Figure 7 shows the ability of 16 antisense oligonucleotides to inhibit mutant KRAS expression in A431 cells. The A431 cells have been genetically-engineered to have the

KRAS wild-type allele removed and individual A431 clones were created to express the human KRAS mutant alleles, either KRAS G12C, KRAS G12D, KRAS G12V, or KRAS G13D (as shown); thus controlling for gymnotic delivery mechanisms, oligonucleotide trafficking and RNase H silencing activity.

[0029] Figure 8 shows the ability of 6 antisense oligonucleotides to inhibit mutant KRAS expression in genetically-engineered A431 cells at different concentrations.

[0030] Figure 9 shows the ability of chemically-modified ASO16 antisense oligonucleotides to inhibit mutant KRAS expression in genetically-engineered A431 cells.

[0031] Figure 10 shows a dose response of KRAS G12C specific ASOs.

[0032] Figure 11 shows an improvement in wild-type KRAS sparing with G12C specific ASOs.

[0033] Figure 12 shows the activity of fully modified siRNAs targeted to the KRAS G12C mutation in genetically-engineered A431 cells expressing KRAS G12C.

[0034] Figure 13 shows the activity of fully modified siRNAs targeted to the KRAS G12C mutation in genetically-engineered A431 cells expressing KRAS G12C.

[0035] Figure 14 shows the activity of fully modified siRNAs targeted to the KRAS G12D mutation in genetically-engineered A431 cells expressing KRAS G12D.

[0036] Figure 15 shows the activity of fully modified siRNAs targeted to the KRAS G12D mutation in genetically-engineered A431 cells expressing KRAS G12D.

[0037] Figure 16 shows the activity of fully modified siRNAs targeted to the KRAS G12V mutation in genetically-engineered A431 cells expressing KRAS G12V.

[0038] Figure 17 shows the activity of fully modified siRNAs targeted to the KRAS G12V mutation in genetically-engineered A431 cells expressing KRAS G12V.

[0039] Figure 18 shows the activity of fully modified siRNAs targeted to the KRAS G13D mutation in genetically-engineered A431 cells expressing KRAS G13D.

[0040] Figure 19 shows the activity of fully modified siRNAs targeted to the KRAS G13D mutation in genetically-engineered A431 cells expressing KRAS G13D.

[0041] Figure 20 shows the results of cell viability experiments with G12D-targeted siRNAs.

[0042] Figure 21 shows the results of cell viability experiments with G12D-targeted siRNAs.

[0043] Figure 22 shows the results of cell viability experiments with G13D-targeted siRNAs.

[0044] Figure 23 shows the results of cell viability experiments with G13D-targeted siRNAs.

[0045] Figure 24 show in vivo evidence for KRAS silencing in HCT116 tumors.

[0046] Figure 25 shows the results of cell viability experiments with G12V-targeted siRNAs.

[0047] Figure 26 shows the results of cell viability experiments with G12V-targeted siRNAs.

[0048] Figure 27 shows inhibition of mutant KRAS expression and wild-type sparing by EFTX-D1 siRNA.

[0049] Figure 28 shows the activity of fully modified siRNAs targeted to KRAS in HCT116 (KRAS G13D mutant) and LU65 (KRAS G12C mutant) cells.

DETAILED DESCRIPTION OF THE INVENTION

[0050] The present invention will now be described in more detail with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

[0051] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. All publications, patent applications, patents, patent publications and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented.

[0052] Nucleotide sequences are presented herein by single strand only, in the 5' to 3' direction, from left to right, unless specifically indicated otherwise. Nucleotides and amino acids are represented herein in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission, or (for amino acids) by either the one-letter code, or the three letter code, both in accordance with 37 C.F.R. §1.822 and established usage.

[0053] Except as otherwise indicated, standard methods known to those skilled in the art may be used for cloning genes, amplifying and detecting nucleic acids, and the like. Such techniques are known to those skilled in the art. *See, e.g., Sambrook et al., Molecular*

Cloning: A Laboratory Manual 2nd Ed. (Cold Spring Harbor, NY, 1989); Ausubel *et al.* Current Protocols in Molecular Biology (Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York).

[0054] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination.

[0055] Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted.

[0056] To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.

Definitions

[0057] As used in the description of the invention and the appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0058] Also as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).

[0059] The term “about,” as used herein when referring to a measurable value such as an amount of polypeptide, dose, time, temperature, enzymatic activity or other biological activity and the like, is meant to encompass variations of $\pm 20\%$, $\pm 10\%$, $\pm 5\%$, $\pm 1\%$, $\pm 0.5\%$, or even $\pm 0.1\%$ of the specified amount.

[0060] As used herein, the transitional phrase “consisting essentially of” (and grammatical variants) is to be interpreted as encompassing the recited materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. Thus, the term “consisting essentially of” as used herein should not be interpreted as equivalent to “comprising.”

[0061] The term “consists essentially of” (and grammatical variants), as applied to a polynucleotide sequence of this invention, means a polynucleotide that consists of both the recited sequence (*e.g.*, SEQ ID NO) and a total of ten or less (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) additional nucleotides on the 5' and/or 3' ends of the recited sequence such that the function of the polynucleotide is not materially altered. The total of ten or less additional nucleotides includes the total number of additional nucleotides on both ends added together.

The term “materially altered,” as applied to polynucleotides of the invention, refers to an increase or decrease in ability to inhibit expression of a target mRNA of at least about 50% or more as compared to the expression level of a polynucleotide consisting of the recited sequence.

[0062] The term “enhance” or “increase” refers to an increase in the specified parameter of at least about 1.25-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, 10-fold, twelve-fold, or even fifteen-fold.

[0063] The term “inhibit” or “reduce” or grammatical variations thereof as used herein refers to a decrease or diminishment in the specified level or activity of at least about 15%, 25%, 35%, 40%, 50%, 60%, 75%, 80%, 90%, 95% or more. In particular embodiments, the inhibition or reduction results in little or essentially no detectable activity (at most, an insignificant amount, *e.g.*, less than about 10% or even 5%).

[0064] A “therapeutically effective” amount as used herein is an amount that provides some improvement or benefit to the subject. Alternatively stated, a “therapeutically effective” amount is an amount that will provide some alleviation, mitigation, or decrease in at least one clinical symptom in the subject (*e.g.*, in the case of cancer, reduction in tumor burden, prevention of further tumor growth, prevention of metastasis, or increase in survival time). Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

[0065] By the terms “treat,” “treating,” or “treatment of,” it is intended that the severity of the subject's condition is reduced or at least partially improved or modified and that some alleviation, mitigation or decrease in at least one clinical symptom is achieved.

[0066] “Prevent” or “preventing” or “prevention” refer to prevention or delay of the onset of the disorder and/or a decrease in the severity of the disorder in a subject relative to the severity that would develop in the absence of the methods of the invention. The prevention can be complete, *e.g.*, the total absence of cancer in a subject. The prevention can also be partial, such that the occurrence or severity of cancer in a subject is less than that which would have occurred without the present invention.

[0067] As used herein, “nucleic acid,” “nucleotide sequence,” and “polynucleotide” are used interchangeably and encompass both RNA and DNA, including cDNA, genomic DNA, mRNA, synthetic (*e.g.*, chemically synthesized) DNA or RNA and chimeras of RNA and DNA. The term polynucleotide, nucleotide sequence, or nucleic acid refers to a chain of nucleotides without regard to length of the chain. The nucleic acid can be double-stranded or single-stranded. Where single-stranded, the nucleic acid can be a sense strand or an antisense

strand. The nucleic acid can be synthesized using oligonucleotide analogs or derivatives (*e.g.*, inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases. The present invention further provides a nucleic acid that is the complement (which can be either a full complement or a partial complement) of a nucleic acid, nucleotide sequence, or polynucleotide of this invention. When dsRNA is produced synthetically, less common bases, such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others can also be used for antisense, dsRNA, and ribozyme pairing. For example, polynucleotides that contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression. Other modifications, such as modification to the phosphodiester backbone, or the 2'-hydroxy in the ribose sugar group of the RNA can also be made.

[0068] An “isolated polynucleotide” is a nucleotide sequence (*e.g.*, DNA or RNA) that is not immediately contiguous with nucleotide sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding (*e.g.*, promoter) sequences that are immediately contiguous to a coding sequence. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment), independent of other sequences. It also includes a recombinant DNA that is part of a hybrid nucleic acid encoding an additional polypeptide or peptide sequence. An isolated polynucleotide that includes a gene is not a fragment of a chromosome that includes such gene, but rather includes the coding region and regulatory regions associated with the gene, but no additional genes naturally found on the chromosome.

[0069] The term “isolated” can refer to a nucleic acid, nucleotide sequence or polypeptide that is substantially free of cellular material, viral material, and/or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an “isolated fragment” is a fragment of a nucleic acid, nucleotide sequence or polypeptide that is not naturally occurring as a fragment and would not be found in the natural state. “Isolated” does not mean that the preparation is technically pure (homogeneous), but it is sufficiently pure to provide the polypeptide or nucleic acid in a form in which it can be used for the intended purpose.

[0070] An “isolated cell” refers to a cell that is separated from other components with which it is normally associated in its natural state. For example, an isolated cell can be a cell in culture medium and/or a cell in a pharmaceutically acceptable carrier of this invention. Thus, an isolated cell can be delivered to and/or introduced into a subject. In some embodiments, an isolated cell can be a cell that is removed from a subject and manipulated as described herein *ex vivo* and then returned to the subject.

[0071] The term “fragment,” as applied to a polynucleotide, will be understood to mean a nucleotide sequence of reduced length relative to a reference nucleic acid or nucleotide sequence and comprising, consisting essentially of, and/or consisting of a nucleotide sequence of contiguous nucleotides identical or almost identical (*e.g.*, 90%, 92%, 95%, 98%, 99% identical) to the reference nucleic acid or nucleotide sequence. Such a nucleic acid fragment according to the invention may be, where appropriate, included in a larger polynucleotide of which it is a constituent. In some embodiments, such fragments can comprise, consist essentially of, and/or consist of oligonucleotides having a length of at least about 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, or more consecutive nucleotides of a nucleic acid or nucleotide sequence according to the invention.

[0072] The term “fragment,” as applied to a polypeptide, will be understood to mean an amino acid sequence of reduced length relative to a reference polypeptide or amino acid sequence and comprising, consisting essentially of, and/or consisting of an amino acid sequence of contiguous amino acids identical or almost identical (*e.g.*, 90%, 92%, 95%, 98%, 99% identical) to the reference polypeptide or amino acid sequence. Such a polypeptide fragment according to the invention may be, where appropriate, included in a larger polypeptide of which it is a constituent. In some embodiments, such fragments can comprise, consist essentially of, and/or consist of peptides having a length of at least about 4, 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, or more consecutive amino acids of a polypeptide or amino acid sequence according to the invention.

[0073] A “vector” is any nucleic acid molecule for the cloning of and/or transfer of a nucleic acid into a cell. A vector may be a replicon to which another nucleotide sequence may be attached to allow for replication of the attached nucleotide sequence. A “replicon” can be any genetic element (*e.g.*, plasmid, phage, cosmid, chromosome, viral genome) that functions as an autonomous unit of nucleic acid replication *in vivo*, *i.e.*, capable of replication under its own control. The term “vector” includes both viral and nonviral (*e.g.*, plasmid) nucleic acid molecules for introducing a nucleic acid into a cell *in vitro*, *ex vivo*, and/or *in vivo*. A large number of vectors known in the art may be used to manipulate nucleic acids,

incorporate response elements and promoters into genes, *etc.* For example, the insertion of the nucleic acid fragments corresponding to response elements and promoters into a suitable vector can be accomplished by ligating the appropriate nucleic acid fragments into a chosen vector that has complementary cohesive termini. Alternatively, the ends of the nucleic acid molecules may be enzymatically modified or any site may be produced by ligating nucleotide sequences (linkers) to the nucleic acid termini. Such vectors may be engineered to contain sequences encoding selectable markers that provide for the selection of cells that contain the vector and/or have incorporated the nucleic acid of the vector into the cellular genome. Such markers allow identification and/or selection of host cells that incorporate and express the proteins encoded by the marker. A “recombinant” vector refers to a viral or non-viral vector that comprises one or more heterologous nucleotide sequences (*i.e.*, transgenes), *e.g.*, two, three, four, five or more heterologous nucleotide sequences.

[0074] Viral vectors have been used in a wide variety of gene delivery applications in cells, as well as living animal subjects. Viral vectors that can be used include, but are not limited to, retrovirus, lentivirus, adeno-associated virus, poxvirus, alphavirus, baculovirus, vaccinia virus, herpes virus, Epstein-Barr virus, and/or adenovirus vectors. Non-viral vectors include, but are not limited to, plasmids, liposomes, electrically charged lipids (cytofectins), nucleic acid-protein complexes, and biopolymers. In addition to a nucleic acid of interest, a vector may also comprise one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (delivery to specific tissues, duration of expression, *etc.*).

[0075] Vectors may be introduced into the desired cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a nucleic acid vector transporter (*see, e.g.*, Wu *et al.*, *J. Biol. Chem.* 267:963 (1992); Wu *et al.*, *J. Biol. Chem.* 263:14621 (1988); and Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990).

[0076] In some embodiments, a polynucleotide of this invention can be delivered to a cell *in vivo* by lipofection. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome-mediated transfection can be used to prepare liposomes for *in vivo* transfection of a nucleotide sequence of this invention (Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413 (1987); Mackey, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 85:8027 (1988); and Ulmer *et al.*, *Science* 259:1745 (1993)). The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively

charged cell membranes (Felgner *et al.*, *Science* 337:387 (1989)). Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. The use of lipofection to introduce exogenous nucleotide sequences into specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cell types would be particularly preferred in a tissue with cellular heterogeneity, such as pancreas, liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting (Mackey, *et al.*, 1988, *supra*). Targeted peptides, *e.g.*, hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

[0077] In various embodiments, other molecules can be used for facilitating delivery of a nucleic acid *in vivo*, such as a cationic oligopeptide (*e.g.*, WO95/21931), peptides derived from nucleic acid binding proteins (*e.g.*, WO96/25508), and/or a cationic polymer (*e.g.*, WO95/21931).

[0078] It is also possible to introduce a vector *in vivo* as naked nucleic acid (see U.S. Patent Nos. 5,693,622, 5,589,466 and 5,580,859). Receptor-mediated nucleic acid delivery approaches can also be used (Curiel *et al.*, *Hum. Gene Ther.* 3:147 (1992); Wu *et al.*, *J. Biol. Chem.* 262:4429 (1987)).

[0079] As used herein, the terms “protein” and “polypeptide” are used interchangeably and encompass both peptides and proteins, unless indicated otherwise.

[0080] A “fusion protein” is a polypeptide produced when two heterologous nucleotide sequences or fragments thereof coding for two (or more) different polypeptides not found fused together in nature are fused together in the correct translational reading frame.

Illustrative fusion polypeptides include fusions of a polypeptide of the invention (or a fragment thereof) to all or a portion of glutathione-S-transferase, maltose-binding protein, or a reporter protein (*e.g.*, Green Fluorescent Protein, β -glucuronidase, β -galactosidase, luciferase, *etc.*), hemagglutinin, c-myc, FLAG epitope, *etc.*

[0081] By the term “express” or “expression” of a polynucleotide coding sequence, it is meant that the sequence is transcribed, and optionally, translated. Typically, according to the present invention, expression of a coding sequence of the invention will result in production of the polypeptide of the invention. The entire expressed polypeptide or fragment can also function in intact cells without purification.

[0082] As used herein, the term “gene” refers to a nucleic acid molecule capable of being used to produce mRNA, antisense RNA, miRNA, and the like. Genes may or may not be capable of being used to produce a functional protein. Genes can include both coding and non-coding regions (*e.g.*, introns, regulatory elements, promoters, enhancers, termination sequences and 5’ and 3’ untranslated regions). A gene may be “isolated” by which is meant a nucleic acid that is substantially or essentially free from components normally found in association with the nucleic acid in its natural state. Such components include other cellular material, culture medium from recombinant production, and/or various chemicals used in chemically synthesizing the nucleic acid.

[0083] As used herein, “complementary” polynucleotides are those that are capable of base pairing according to the standard Watson-Crick complementarity rules. Specifically, purines will base pair with pyrimidines to form a combination of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. For example, the sequence “A-G-T” binds to the complementary sequence “T-C-A.” It is understood that two polynucleotides may hybridize to each other even if they are not completely complementary to each other, provided that each has at least one region that is substantially complementary to the other.

[0084] The terms “complementary” or “complementarity,” as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. Complementarity between two single-stranded molecules may be “partial,” in which only some of the nucleotides bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands.

[0085] As used herein, the terms “substantially complementary” or “partially complementary” mean that two nucleic acid sequences are complementary at least about 50%, 60%, 70%, 80% or 90% of their nucleotides. In some embodiments, the two nucleic acid sequences can be complementary at least at 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of their nucleotides. The terms “substantially complementary” and “partially complementary” can also mean that two nucleic acid sequences can hybridize under high stringency conditions and such conditions are well known in the art.

[0086] As used herein, “heterologous” refers to a nucleic acid sequence that either originates from another species or is from the same species or organism but is modified from either its original form or the form primarily expressed in the cell. Thus, a nucleotide

sequence derived from an organism or species different from that of the cell into which the nucleotide sequence is introduced, is heterologous with respect to that cell and the cell's descendants. In addition, a heterologous nucleotide sequence includes a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, *e.g.*, a different copy number, and/or under the control of different regulatory sequences than that found in nature.

[0087] As used herein, the terms “contacting,” “introducing” and “administering” are used interchangeably, and refer to a process by which dsRNA of the present invention or a nucleic acid molecule encoding a dsRNA of this invention is delivered to a cell, in order to inhibit or alter or modify expression of a target gene. The dsRNA may be administered in a number of ways, including, but not limited to, direct introduction into a cell (*i.e.*, intracellularly) and/or extracellular introduction into a cavity, interstitial space, or into the circulation of the organism.

[0088] “Introducing” in the context of a cell or organism means presenting the nucleic acid molecule to the organism and/or cell in such a manner that the nucleic acid molecule gains access to the interior of a cell. Where more than one nucleic acid molecule is to be introduced these nucleic acid molecules can be assembled as part of a single polynucleotide or nucleic acid construct, or as separate polynucleotide or nucleic acid constructs, and can be located on the same or different nucleic acid constructs. Accordingly, these polynucleotides can be introduced into cells in a single transformation event or in separate transformation events. Thus, the term “transformation” as used herein refers to the introduction of a heterologous nucleic acid into a cell. Transformation of a cell may be stable or transient.

[0089] “Transient transformation” in the context of a polynucleotide means that a polynucleotide is introduced into the cell and does not integrate into the genome of the cell.

[0090] By “stably introducing” or “stably introduced” in the context of a polynucleotide introduced into a cell, it is intended that the introduced polynucleotide is stably incorporated into the genome of the cell, and thus the cell is stably transformed with the polynucleotide.

[0091] “Stable transformation” or “stably transformed” as used herein means that a nucleic acid molecule is introduced into a cell and integrates into the genome of the cell. As such, the integrated nucleic acid molecule is capable of being inherited by the progeny thereof, more particularly, by the progeny of multiple successive generations. “Genome” as used herein includes the nuclear and mitochondrial genome, and therefore includes integration of the nucleic acid into, for example, the mitochondrial genome. Stable transformation as used

herein can also refer to a transgene that is maintained extrachromasomally, for example, as a minichromosome.

[0092] Transient transformation may be detected by, for example, an enzyme-linked immunosorbent assay (ELISA) or Western blot, which can detect the presence of a peptide or polypeptide encoded by one or more transgene introduced into an organism. Stable transformation of a cell can be detected by, for example, a Southern blot hybridization assay of genomic DNA of the cell with nucleic acid sequences which specifically hybridize with a nucleotide sequence of a transgene introduced into an organism. Stable transformation of a cell can be detected by, for example, a Northern blot hybridization assay of RNA of the cell with nucleic acid sequences which specifically hybridize with a nucleotide sequence of a transgene introduced into an organism. Stable transformation of a cell can also be detected by, *e.g.*, a polymerase chain reaction (PCR) or other amplification reactions as are well known in the art, employing specific primer sequences that hybridize with target sequence(s) of a transgene, resulting in amplification of the transgene sequence, which can be detected according to standard methods. Transformation can also be detected by direct sequencing and/or hybridization protocols well known in the art.

[0093] Embodiments of the invention are directed to expression cassettes designed to express the nucleic acids of the present invention. As used herein, “expression cassette” means a nucleic acid molecule having at least a control sequence operably linked to a nucleotide sequence of interest. In this manner, for example, promoters in operable interaction with the nucleotide sequences for the siRNAs of the invention are provided in expression cassettes for expression in an organism or cell.

[0094] As used herein, the term “promoter” refers to a region of a nucleotide sequence that incorporates the necessary signals for the efficient expression of a coding sequence. This may include sequences to which an RNA polymerase binds, but is not limited to such sequences and can include regions to which other regulatory proteins bind together with regions involved in the control of protein translation and can also include coding sequences.

[0095] Furthermore, a “promoter” of this invention is a promoter capable of initiating transcription in a cell of an organism. Such promoters include those that drive expression of a nucleotide sequence constitutively, those that drive expression when induced, and those that drive expression in a tissue- or developmentally-specific manner, as these various types of promoters are known in the art.

[0096] For purposes of the invention, the regulatory regions (*i.e.*, promoters, transcriptional regulatory regions, and translational termination regions) can be native/analogous to the

organism or cell and/or the regulatory regions can be native/analogous to the other regulatory regions. Alternatively, the regulatory regions may be heterologous to the organism or cell and/or to each other (*i.e.*, the regulatory regions). Thus, for example, a promoter can be heterologous when it is operably linked to a polynucleotide from a species different from the species from which the polynucleotide was derived. Alternatively, a promoter can also be heterologous to a selected nucleotide sequence if the promoter is from the same/analogous species from which the polynucleotide is derived, but one or both (*i.e.*, promoter and polynucleotide) are substantially modified from their original form and/or genomic locus, or the promoter is not the native promoter for the operably linked polynucleotide.

[0097] The choice of promoters to be used depends upon several factors, including, but not limited to, cell- or tissue-specific expression, desired expression level, efficiency, inducibility and selectability. For example, where expression in a specific tissue or organ is desired, a tissue-specific promoter can be used. In contrast, where expression in response to a stimulus is desired, an inducible promoter can be used. Where continuous expression is desired throughout the cells of an organism, a constitutive promoter can be used. It is a routine matter for one of skill in the art to modulate the expression of a nucleotide sequence by appropriately selecting and positioning promoters and other regulatory regions relative to that sequence.

[0098] In addition to the promoters described above, the expression cassette also can include other regulatory sequences. As used herein, “regulatory sequences” means nucleotide sequences located upstream (5' non-coding sequences), within or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences include, but are not limited to, enhancers, introns, translation leader sequences and polyadenylation signal sequences.

[0099] The expression cassette also can optionally include a transcriptional and/or translational termination region (*i.e.*, termination region) that is functional in the organism. A variety of transcriptional terminators are available for use in expression cassettes and are responsible for the termination of transcription beyond the transgene and correct mRNA polyadenylation. The termination region may be native to the transcriptional initiation region, may be native to the operably linked nucleotide sequence of interest, may be native to the host, or may be derived from another source (*i.e.*, foreign or heterologous to the promoter, the nucleotide sequence of interest, the host, or any combination thereof).

[0100] A signal sequence can be operably linked to nucleic acids of the present invention to direct the nucleotide sequence into a cellular compartment. In this manner, the expression cassette will comprise a nucleotide sequence encoding the siRNA operably linked to a nucleic acid sequence for the signal sequence. The signal sequence may be operably linked at the N- or C- terminus of the siRNA.

[0101] Regardless of the type of regulatory sequence(s) used, they can be operably linked to the nucleotide sequence of the siRNA. As used herein, “operably linked” means that elements of a nucleic acid construct such as an expression cassette are configured so as to perform their usual function. Thus, regulatory or control sequences (*e.g.*, promoters) operably linked to a nucleotide sequence of interest are capable of effecting expression of the nucleotide sequence of interest. The control sequences need not be contiguous with the nucleotide sequence of interest, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated, yet transcribed, sequences can be present between a promoter and a coding sequence, and the promoter sequence can still be considered “operably linked” to the coding sequence. A nucleotide sequence of the present invention (*i.e.*, a siRNA) can be operably linked to a regulatory sequence, thereby allowing its expression in a cell and/or subject.

[0102] The expression cassette also can include a nucleotide sequence for a selectable marker, which can be used to select a transformed organism or cell. As used herein, “selectable marker” means a nucleic acid that when expressed imparts a distinct phenotype to the organism or cell expressing the marker and thus allows such transformed organisms or cells to be distinguished from those that do not have the marker. Such a nucleic acid may encode either a selectable or screenable marker, depending on whether the marker confers a trait that can be selected for by chemical means, such as by using a selective agent (*e.g.*, an antibiotic or the like), or on whether the marker is simply a trait that one can identify through observation or testing, such as by screening (. Of course, many examples of suitable selectable markers are known in the art and can be used in the expression cassettes described herein.

[0103] In some embodiments of the present invention, the expression cassette can comprise an expression control sequence operatively linked to a nucleotide sequence that is a template for one or both strands of the dsRNA. In further embodiments, a promoter can flank either end of the template nucleotide sequence, wherein the promoters drive expression of each individual DNA strand, thereby generating two complementary (or substantially complementary) RNAs that hybridize and form the dsRNA. In alternative embodiments, the

nucleotide sequence is transcribed into both strands of the dsRNA on one transcription unit, wherein the sense strand is transcribed from the 5' end of the transcription unit and the antisense strand is transcribed from the 3' end, wherein the two strands are separated by about 3 to about 500 basepairs, and wherein after transcription, the RNA transcript folds on itself to form a short hairpin RNA (shRNA) molecule.

[0104] As used herein “sequence identity” refers to the extent to which two optimally aligned polynucleotide or polypeptide sequences are invariant throughout a window of alignment of components, *e.g.*, nucleotides or amino acids. “Identity” can be readily calculated by known methods including, but not limited to, those described in: *Computational Molecular Biology* (Lesk, A. M., ed.) Oxford University Press, New York (1988); *Biocomputing: Informatics and Genome Projects* (Smith, D. W., ed.) Academic Press, New York (1993); *Computer Analysis of Sequence Data, Part I* (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, New Jersey (1994); *Sequence Analysis in Molecular Biology* (von Heinje, G., ed.) Academic Press (1987); and *Sequence Analysis Primer* (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).

[0105] As used herein, the term “substantially identical” or “corresponding to” means that two nucleic acid sequences have at least 60%, 70%, 80% or 90% sequence identity. In some embodiments, the two nucleic acid sequences can have at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of sequence identity.

[0106] An “identity fraction” for aligned segments of a test sequence and a reference sequence is the number of identical components which are shared by the two aligned sequences divided by the total number of components in reference sequence segment, *i.e.*, the entire reference sequence or a smaller defined part of the reference sequence.

[0107] As used herein, the term “percent sequence identity” or “percent identity” refers to the percentage of identical nucleotides in a linear polynucleotide sequence of a reference (“query”) polynucleotide molecule (or its complementary strand) as compared to a test (“subject”) polynucleotide molecule (or its complementary strand) when the two sequences are optimally aligned (with appropriate nucleotide insertions, deletions, or gaps totaling less than 20 percent of the reference sequence over the window of comparison). In some embodiments, “percent identity” can refer to the percentage of identical amino acids in an amino acid sequence.

[0108] Optimal alignment of sequences for aligning a comparison window are well known to those skilled in the art and may be conducted by tools such as the local homology algorithm of Smith and Waterman, the homology alignment algorithm of Needleman and

Wunsch, the search for similarity method of Pearson and Lipman, and optionally by computerized implementations of these algorithms such as GAP, BESTFIT, FASTA, and TFASTA available as part of the GCG® Wisconsin Package® (Accelrys Inc., Burlington, Mass.). Percent sequence identity is represented as the identity fraction multiplied by 100. The comparison of one or more polynucleotide sequences may be to a full-length polynucleotide sequence or a portion thereof, or to a longer polynucleotide sequence. For purposes of this invention “percent identity” may also be determined using BLASTX version 2.0 for translated nucleotide sequences and BLASTN version 2.0 for polynucleotide sequences.

[0109] The percent of sequence identity can be determined using the “Best Fit” or “Gap” program of the Sequence Analysis Software Package™ (Version 10; Genetics Computer Group, Inc., Madison, Wis.). “Gap” utilizes the algorithm of Needleman and Wunsch (Needleman and Wunsch, *J Mol. Biol.* 48:443-453, 1970) to find the alignment of two sequences that maximizes the number of matches and minimizes the number of gaps. “BestFit” performs an optimal alignment of the best segment of similarity between two sequences and inserts gaps to maximize the number of matches using the local homology algorithm of Smith and Waterman (Smith and Waterman, *Adv. Appl. Math.*, 2:482-489, 1981, Smith *et al.*, *Nucleic Acids Res.* 11:2205-2220, 1983).

[0110] Useful methods for determining sequence identity are also disclosed in Guide to Huge Computers (Martin J. Bishop, ed., Academic Press, San Diego (1994)), and Carillo, H., and Lipton, D., (*Applied Math* 48:1073(1988)). More particularly, preferred computer programs for determining sequence identity include but are not limited to the Basic Local Alignment Search Tool (BLAST) programs which are publicly available from National Center Biotechnology Information (NCBI) at the National Library of Medicine, National Institute of Health, Bethesda, Md. 20894; see BLAST Manual, Altschul *et al.*, NCBI, NLM, NIH; (Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990)); version 2.0 or higher of BLAST programs allows the introduction of gaps (deletions and insertions) into alignments; for peptide sequence BLASTX can be used to determine sequence identity; and, for polynucleotide sequence BLASTN can be used to determine sequence identity.

[0111] As used herein, “RNAi” or “RNA interference” refers to the process of sequence-specific post-transcriptional gene silencing, mediated by double-stranded RNA (dsRNA). As used herein, “dsRNA” refers to RNA that is partially or completely double stranded. Double stranded RNA is also referred to as small interfering RNA (siRNA), small interfering nucleic acid (siNA), microRNA (miRNA), and the like. In the RNAi process, dsRNA comprising a

first (antisense) strand that is complementary to a portion of a target gene and a second (sense) strand that is fully or partially complementary to the first antisense strand is introduced into an organism. After introduction into the organism, the target gene-specific dsRNA is processed into relatively small fragments (siRNAs) and can subsequently become distributed throughout the organism, leading to a loss-of-function mutation having a phenotype that, over the period of a generation, may come to closely resemble the phenotype arising from a complete or partial deletion of the target gene.

[0112] MicroRNAs (miRNAs) are non-protein coding RNAs, generally of between about 18 to about 25 nucleotides in length. These miRNAs direct cleavage in *trans* of target transcripts, negatively regulating the expression of genes involved in various regulation and development pathways (Bartel, *Cell*, 116:281-297 (2004); Zhang et al. *Dev. Biol.* 289:3-16 (2006)). As such, miRNAs have been shown to be involved in different aspects of growth and development as well as in signal transduction and protein degradation. Since the first miRNAs were discovered in plants (Reinhart et al. *Genes Dev.* 16:1616-1626 (2002), Park et al. *Curr. Biol.* 12:1484-1495 (2002)) many hundreds have been identified. Many microRNA genes (MIR genes) have been identified and made publicly available in a database (miRBase; microrna.sanger.ac.uk/sequences). miRNAs are also described in U.S. Patent Publications 2005/0120415 and 2005/144669A1, the entire contents of which are incorporated by reference herein.

[0113] Genes encoding miRNAs yield primary miRNAs (termed a “pri-miRNA”) of 70 to 300 bp in length that can form imperfect stem-loop structures. A single pri-miRNA may contain from one to several miRNA precursors. In animals, pri-miRNAs are processed in the nucleus into shorter hairpin RNAs of about 65 nt (pre-miRNAs) by the RNaseIII enzyme Drosha and its cofactor DGCR8/Pasha. The pre-miRNA is then exported to the cytoplasm, where it is further processed by another RNaseIII enzyme, Dicer, releasing a miRNA/miRNA* duplex of about 22 nt in size. Many reviews on microRNA biogenesis and function are available, for example, *see*, Bartel *Cell* 116:281-297 (2004), Murchison et al. *Curr. Opin. Cell Biol.* 16:223-229 (2004), Dugas et al. *Curr. Opin. Plant Biol.* 7:512-520 (2004) and Kim *Nature Rev. Mol. Cell Biol.* 6:376-385 (2005).

RNA Molecules

[0114] The present invention is based on the identification of RNA molecules that inhibit expression of mutant KRAS sequences while sparing expression of WT KRAS. Accordingly, one aspect of the invention relates to a double stranded RNA molecule comprising an

antisense strand and a sense strand, wherein the nucleotide sequence of the antisense strand is complementary to a region of the nucleotide sequence of a synthetic human KRAS gene that contains the missense mutations G12C, G12D, and G13D or the missense mutations G12C, G12V, and G13D, the region consisting essentially of about 18 to about 25 consecutive nucleotides; wherein the double stranded RNA molecule inhibits expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D and minimally inhibits expression of wild-type human KRAS. The region of the KRAS gene targeted by the RNA molecule comprises the nucleotides encoding residues 12 and 13. The RNA molecules provide decreased expression of mutant KRAS in a cell as compared to a wild-type variety of the cell (*e.g.*, a control cell or nontransformed cell). In some embodiments, expression of mutant KRAS is inhibited by at least about 50%, *e.g.*, at least about 50%, 60%, 70%, 80%, 90%, 95%, or more.

[0115] A human KRAS gene containing the missense mutations G12C, G12D, and G13D or the missense mutations G12C, G12V, and G13D does not exist in nature. Examples of a region of such artificial gene sequences include **SEQ ID NOS:37 and 38**, with the mutations relative to the corresponding WT KRAS sequence (**SEQ ID NO:39**) underlined.

SEQ ID NO:37

ACTGAATATAAACTTGTGGTAGTTGGAGCTTATGACGTAGGCAAGAGTGCCTTGA
CGATACAG

SEQ ID NO:38

ACTGAATATAAACTTGTGGTAGTTGGAGCTTTTTGACGTAGGCAAGAGTGCCTTGA
CGATACAG

SEQ ID NO:39

ACTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTG
ACGATACAG

[0116] The double stranded RNA molecule can comprise, consist essentially of, or consist of about 18 to about 25 nucleotides (*e.g.*, 18, 19, 20, 21, 22, 23, 24, or 25 or any range therein). Additional nucleotides can be added at the 3' end, the 5' end or both the 3' and 5' ends to facilitate manipulation of the RNA molecule but that do not materially affect the basic characteristics or function of the double stranded RNA molecule in RNA interference

(RNAi). Additionally, one or two nucleotides can be deleted from one or both ends of any of the sequences disclosed herein that do not materially affect the basic characteristics or function of the double stranded RNA molecule in RNAi. The term “materially affect” as used herein refers to a change in the ability to inhibit expression of the protein encoded by the mRNA (*e.g.*, WT KRAS) by no more than about 50%, *e.g.*, no more than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or less. Such additional nucleotides can be nucleotides that extend the complementarity of the antisense strand along the target sequence and/or such nucleotides can be nucleotides that facilitate manipulation of the RNA molecule or a nucleic acid molecule encoding the RNA molecule, as would be known to one of skill in the art. For example, a TT overhang at the 3' end may be present, which is used to stabilize the siRNA duplex and does not affect the specificity of the siRNA.

[0117] The dsRNA of the invention may optionally comprise a single stranded overhang at either or both ends. The double-stranded structure may be formed by a single self-complementary RNA strand (*i.e.*, forming a hairpin loop) or two complementary RNA strands. RNA duplex formation may be initiated either inside or outside the cell. When the dsRNA of the invention forms a hairpin loop, it may optionally comprise an intron and/or a nucleotide spacer, which is a stretch of nucleotides between the complementary RNA strands, to stabilize the hairpin sequence in cells. The RNA may be introduced in an amount that allows delivery of at least one copy per cell. Higher doses of double-stranded material may yield more effective inhibition.

[0118] In particular embodiments, the present invention provides double stranded RNA containing a nucleotide sequence that is fully complementary to a region of the target gene for inhibition. However, it is to be understood that 100% complementarity between the antisense strand of the double stranded RNA molecule and the target sequence is not required to practice the present invention. Thus, sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence can be tolerated. RNA sequences with insertions, deletions, and single point mutations relative to the target sequence may also be effective for inhibition.

[0119] In certain embodiments, the nucleotide sequence of the antisense strand contains at least 3 mismatches with the nucleotide sequence of wild-type human KRAS such that the RNA molecule does not target WT KRAS and only minimally inhibits expression of WT KRAS. As used herein, “minimally inhibits expression” means that expression of the protein encoded by the mRNA (*e.g.*, WT KRAS) is inhibited by no more than about 50%, *e.g.*, no more than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or less.

[0120] In certain embodiments, the nucleotide sequence of the antisense strand contains no more than 2 mismatches with the nucleotide sequence of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D. In some embodiments, the nucleotide sequence of the antisense strand contains at least 3 mismatches with the nucleotide sequence of wild-type human KRAS and contains no more than 2 mismatches with the nucleotide sequence of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D.

[0121] In some embodiments, the nucleotide sequence of the sense strand comprises a nucleotide sequence that is at least about 80% identical to the nucleotide sequence of any of **SEQ ID NOS:1-9**, *e.g.*, at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical to the nucleotide sequence of any of **SEQ ID NOS:1-9**. In some embodiments, the nucleotide sequence of the sense strand comprises, consists essentially of, or consist of the nucleotide sequence of any of **SEQ ID NOS:1-9**.

SEQ ID NO:1	GAGCUUAUGACGUAGGCAA
SEQ ID NO:2	AGUUGGAGCUUAUGACGUA
SEQ ID NO:3	GGUAGUUGGAGCUUAUGAC
SEQ ID NO:4	GUAGUUGGAGCUUAUGACG
SEQ ID NO:5	UAGUUGGAGCUUAUGACGU
SEQ ID NO:6	GUUGGAGCUUAUGACGUAG
SEQ ID NO:7	UUGGAGCUUAUGACGUAGG
SEQ ID NO:8	UGGAGCUUAUGACGUAGGC
SEQ ID NO:9	GGAGCUUAUGACGUAGGCA

[0122] In some embodiments, the nucleotide sequence of the antisense strand comprises a nucleotide sequence that is at least about 80% identical to the nucleotide sequence of any of **SEQ ID NOS:19-27**, *e.g.*, at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical to the nucleotide sequence of any of **SEQ ID NOS: 19-27**. In some embodiments, the nucleotide sequence of the antisense strand comprises, consists essentially of, or consist of the nucleotide sequence of any of **SEQ ID NOS: 19-27**.

SEQ ID NO:19	UUGCCUACGUCAUAAGCUC
SEQ ID NO:20	UACGUCAUAAGCUCCAACU
SEQ ID NO:21	GUCAUAAGCUCCAACUACC

SEQ ID NO:22 CGUCAUAAGCUCCAACUAC
SEQ ID NO:23 ACGUCAUAAGCUCCAACUA
SEQ ID NO:24 CUACGUCAUAAGCUCCAAC
SEQ ID NO:25 CCUACGUCAUAAGCUCCAA
SEQ ID NO:26 GCCUACGUCAUAAGCUCCA
SEQ ID NO:27 UGCCUACGUCAUAAGCUCC

[0123] In some embodiments, one or both of the sense strand and the antisense strand comprises a TT overhang at the 3' end. Thus, in some embodiments, the sense strand comprises a nucleotide sequence that is at least about 80% identical to the nucleotide sequence of any of **SEQ ID NOS:10-18**, *e.g.*, at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical to the nucleotide sequence of any of **SEQ ID NOS: 10-18**. In some embodiments, the nucleotide sequence of the sense strand comprises, consists essentially of, or consist of the nucleotide sequence of any of **SEQ ID NOS: 10-18**.

SEQ ID NO:10 GAGCUUAUGACGUAGGCAAdTdT
SEQ ID NO:11 AGUUGGAGCUUAUGACGUAdTdT
SEQ ID NO:12 GGUAGUUGGAGCUUAUGACdTdT
SEQ ID NO:13 GUAGUUGGAGCUUAUGACGdTdT
SEQ ID NO:14 UAGUUGGAGCUUAUGACGUdTdT
SEQ ID NO:15 GUUGGAGCUUAUGACGUAGdTdT
SEQ ID NO:16 UUGGAGCUUAUGACGUAGGdTdT
SEQ ID NO:17 UGGAGCUUAUGACGUAGGCdTdT
SEQ ID NO:18 GGAGCUUAUGACGUAGGCAdTdT

[0124] In some embodiments, the nucleotide sequence of the antisense strand comprise a nucleotide sequence that is at least about 80% identical to the nucleotide sequence of any of **SEQ ID NOS:28-36**, *e.g.*, at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical to the nucleotide sequence of any of **SEQ ID NOS: 28-36**. In some embodiments, the nucleotide sequence of the antisense strand comprises, consists essentially of, or consist of the nucleotide sequence of any of **SEQ ID NOS: 28-36**.

SEQ ID NO:28 UUGCCUACGUCAUAAGCUCdTdT

SEQ ID NO:29 UACGUCAUAAGCUCCAACUdTdT
SEQ ID NO:30 GUCAUAAGCUCCAACUACcdTdT
SEQ ID NO:31 CGUCAUAAGCUCCAACUACdTdT
SEQ ID NO:32 ACGUCAUAAGCUCCAACUAdTdT
SEQ ID NO:33 CUACGUCAUAAGCUCCAACdTdT
SEQ ID NO:34 CCUACGUCAUAAGCUCCAAdTdT
SEQ ID NO:35 GCCUACGUCAUAAGCUCCAdTdT
SEQ ID NO:36 UGCCUACGUCAUAAGCUCCdTdT

[0125] In some embodiments of this invention, the sense strand of the double stranded RNA molecule can be fully complementary to the antisense strand or the sense strand can be substantially complementary or partially complementary to the antisense strand. By substantially or partially complementary is meant that the sense strand and the antisense strand can be mismatched at about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide pairings. Such mismatches can be introduced into the sense strand sequence, *e.g.*, near the 3' end, to enhance processing of the double stranded RNA molecule by Dicer, to duplicate a pattern of mismatches in a siRNA molecule inserted into a chimeric nucleic acid molecule or artificial microRNA precursor molecule of this invention, and the like, as would be known to one of skill in the art. Such modification will weaken the base pairing at one end of the duplex and generate strand asymmetry, therefore enhancing the chance of the antisense strand, instead of the sense strand, being processed and silencing the intended gene (Geng and Ding "Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing Allele1" *Acta Pharmacol. Sin.* 29:211-216 (2008); Schwarz *et al.* "Asymmetry in the assembly of the RNAi enzyme complex" *Cell* 115:199-208 (2003)).

[0126] The double stranded RNA molecule of the invention may be in the form of any type of RNA interference molecule known in the art. In some embodiments, the double stranded RNA molecule is a small interfering RNA (siRNA) molecule. In other embodiments, the double stranded RNA molecule is a short hairpin RNA (shRNA) molecule. In other embodiments, the double stranded RNA molecule is part of a microRNA precursor molecule.

Antisense Oligonucleotides

[0127] One aspect of the invention relates to an antisense oligonucleotide (ASO) targeted to a synthetic human KRAS mRNA that encodes the missense mutations G12C, G12D, and G13D, wherein the ASO is 16-25 nucleotides in length and comprises or consists essentially

of the sequence TCTTGCCTACGTCATA (**SEQ ID NO:114**). In some embodiments, the ASO is 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length or any range therein. In some embodiments, the ASO is 20, 21, or 22 nucleotides in length. In some embodiments, the ASO is 20 nucleotides in length. In certain embodiments, at least 80% of the unspecified nucleotides in the ASO are complementary to a wild-type human KRAS gene, *e.g.*, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In certain embodiments, at least 80% of the unspecified nucleotides in the ASO are complementary to a mutant human KRAS gene, *e.g.*, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the ASO is 17-25 nucleotides in length and comprises or consists essentially of the sequence CTCTTGCCTACGTCATA (**SEQ ID NO:121**), 18-25 nucleotides in length and ACTCTTGCCTACGTCATA (**SEQ ID NO:122**), or 19-25 nucleotides in length and CACTCTTGCCTACGTCATA (**SEQ ID NO:123**).

[0128] In some embodiments, the ASO comprises, consists essentially of, or consists of the sequence CACTCTTGCCTACGTCATAA (**SEQ ID NO:115**) or a sequence at least 90% identical thereto, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, the ASO comprises, consists essentially of, or consists of the sequence GCACTCTTGCCTACGTCATA (**SEQ ID NO:116**) or a sequence at least 90% identical thereto, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

[0129] The ASO may be comprised of deoxyribonucleotides, ribonucleotides, or a combination thereof.

[0130] In some embodiments, the ASO comprises at least one non-naturally occurring chemical modification. In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotide linkages are chemically modified. In some embodiments, the ASO comprises at least one phosphorothioate linkage. In some embodiments, the ASO comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate linkages. In some embodiments, the ASO comprises all phosphorothioate linkages.

[0131] In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotides are chemically modified. In some embodiments, the ASO comprises at least one modified nucleotide at or near the 5' end and/or the 3' end, *e.g.*, within 5 nucleotides of 5' end and/or the 3' end, *e.g.*, at least 1, 2, 3, 4, or 5 modified nucleotides. In some embodiments, the ASO comprises at least 3 modified nucleotides at each of the 5' end and the 3' end, *e.g.*, at least 4 or at least 5. In some embodiments, at least one of the modified

nucleotides is a 2'—O-methoxyethyl (2'—MOE)-modified nucleotide. In some embodiments, all of the modified nucleotides is a 2'—MOE-modified nucleotide. In some embodiments, the ASO comprises at least 3 2'—MOE-modified nucleotides at each of the 5' end and/or the 3' end, *e.g.*, at least 4 or at least 5.

[0132] In some embodiments, the ASO comprises, consists essentially of, or consists of a sequence selected from:

a) **C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A** (SEQ ID NO:68);

or

b) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A** (SEQ ID NO:69);

wherein * indicates a phosphorothioate linkage and bold indicates a 2'—MOE-modified nucleotide. In some embodiments, the ASO comprises, consists essentially of, or consists of a sequence at least 90% identical to one of SEQ ID NO:68 and SEQ ID NO:69, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

[0133] Another aspect of the invention relates to an ASO targeted to a naturally-occurring human KRAS mRNA encoding a mutation selected from G12C, G12D, G12V, and G13D, wherein the ASO is 16-25 nucleotides in length and comprises or consists essentially of a sequence selected from:

a) TCTTGCCTACGCCACA (SEQ ID NO:117) targeted to a human KRAS mRNA encoding a G12C mutation;

b) TCTTGCCTACGCCATC (SEQ ID NO:118) targeted to a human KRAS mRNA encoding a G12D mutation;

c) TCTTGCCTACGCCAAC (SEQ ID NO:119) targeted to a human KRAS mRNA encoding a G12V mutation;

d) TCTTGCCTACGTCACC (SEQ ID NO:120) targeted to a human KRAS mRNA encoding a G13D mutation; or

e) a sequence at least 90% identical to any one of a) to d);

wherein the antisense oligonucleotide comprises at least one non-naturally occurring chemical modification.

[0134] In some embodiments, the ASO is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOS:117-120.

[0135] In some embodiments, the ASO is 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length or any range therein. In some embodiments, the ASO is 20, 21, or 22 nucleotides in length. In some embodiments, the ASO is 20 nucleotides in length. In certain embodiments, at least 80% of the unspecified nucleotides in the ASO are complementary to a

wild-type human KRAS gene, *e.g.*, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In certain embodiments, at least 80% of the unspecified nucleotides in the ASO are complementary to a mutant human KRAS gene, *e.g.*, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the ASO is 17-25 nucleotides in length and comprises an additional nucleotide C at the 5' end of the sequence of one of **SEQ ID NOS:117-120**. In certain embodiments, the ASO is 18-25 nucleotides in length and comprises additional nucleotides AC at the 5' end of the sequence of one of **SEQ ID NOS:117-120**. In certain embodiments, the ASO is 19-25 nucleotides in length and comprises additional nucleotides CAC at the 5' end of the sequence of one of **SEQ ID NOS:117-120**. In certain embodiments, the ASO is 20-25 nucleotides in length and comprises additional nucleotides GCAC at the 5' end of the sequence of one of **SEQ ID NOS:117-120**.

[0136] In some embodiments, the antisense oligonucleotide consists of a sequence selected from:

- a) GCACTCTTGCCTACGCCACA (**SEQ ID NO:124**) targeted to a human KRAS mRNA encoding a G12C mutation;
- b) GCACTCTTGCCTACGCCATC (**SEQ ID NO:125**) targeted to a human KRAS mRNA encoding a G12D mutation;
- c) GCACTCTTGCCTACGCCAAC (**SEQ ID NO:126**) targeted to a human KRAS mRNA encoding a G12V mutation; or
- d) GCACTCTTGCCTACGTCACC (**SEQ ID NO:127**) targeted to a human KRAS mRNA encoding a G13D mutation.

[0137] The ASO may be comprised of deoxyribonucleotides, ribonucleotides, or a combination thereof.

[0138] In some embodiments, the ASO comprises at least one non-naturally occurring chemical modification. In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotide linkages are chemically modified. In some embodiments, the ASO comprises at least one phosphorothioate linkage. In some embodiments, the ASO comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate linkages. In some embodiments, the ASO comprises all phosphorothioate linkages.

[0139] In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotides are chemically modified. In some embodiments, the ASO comprises at least one modified nucleotide at or near the 5' end and/or the 3' end, *e.g.*, within

5 nucleotides of 5' end and/or the 3' end, *e.g.*, at least 1, 2, 3, 4, or 5 modified nucleotides. In some embodiments, the ASO comprises at least five modified nucleotides at each of the 5' end and the 3' end. In some embodiments, at least one of the modified nucleotides is a 2'—MOE-modified nucleotide. In some embodiments, all of the modified nucleotides is a 2'—MOE-modified nucleotide. In some embodiments, the ASO comprises at least 3 2'—MOE-modified nucleotides at each of the 5' end and/or the 3' end, *e.g.*, at least 4 or at least 5.

[0140] In certain embodiments, the ASO consists of a sequence selected from:

- a) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*A** (SEQ ID NO:70);
 - b) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*T*C** (SEQ ID NO:71);
 - c) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*A*C** (SEQ ID NO:72);
- or
- d) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*C*C** (SEQ ID NO:73);

wherein * indicates a phosphorothioate linkage and bold indicates a 2'—MOE-modified nucleotide. In some embodiments, the ASO comprises, consists essentially of, or consists of a sequence at least 90% identical to one of SEQ ID NOS:70-73, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

[0141] In some embodiments, at least one modified nucleotide is a locked nucleic acid nucleotide, *e.g.*, at least 1, 2, 3, 4, or 5 modified nucleotides. The lock nucleic acid may be, without limitation, a methylene bridge connecting the 2' oxygen and 4' carbon on the ribose to lock the ribose in the 3'-endo (North) conformation.

[0142] In certain embodiments, the ASO consists of a sequence selected from:

- a) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C**A** (SEQ ID NO:74);
- b) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A**+T*C** (SEQ ID NO:75);
- c) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A**+A*C** (SEQ ID NO:76);
- d) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*+T*C*A*C*C** (SEQ ID NO:77);
- e) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A**+C**A** (SEQ ID NO:160); or
- f) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C**+A**+C**A** (SEQ ID NO:161);

wherein * indicates a phosphorothioate linkage, bold indicates a 2'—methoxymethyl-modified nucleotide, and + indicates the following nucleotide is a locked nucleic acid. In some embodiments, the ASO comprises, consists essentially of, or consists of a sequence at least 90% identical to one of SEQ ID NOS:74-77, 160, or 161, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

Chemically-Modified siRNAs

[0143] One aspect of the invention relates to a siRNA molecule targeted to a naturally-occurring human KRAS mRNA encoding a mutation selected from G12C, G12D, G12V, and G13D, wherein the siRNA comprises at least one chemical modification. In some embodiments, the siRNA molecule is fully chemically modified. The term “fully chemically-modified” means that every nucleotide in the siRNA contains a chemical modification. In some embodiments, each nucleotide in the siRNA molecule is modified with a 2'-O-methyl group or a 2'-fluoro group.

[0144] In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotide linkages in the siRNA are chemically modified. In some embodiments, the siRNA comprises at least one phosphorothioate linkage. In some embodiments, the siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate linkages. In some embodiments, the siRNA comprises all phosphorothioate linkages.

[0145] In certain embodiments, the siRNA molecule comprising at least one chemical modification comprises a sense strand and an antisense strand, wherein the siRNA molecule comprises one of the following pairs of sequences:

sense strand of **SEQ ID NO:128** and antisense strand of **SEQ ID NO:129**;
sense strand of **SEQ ID NO:130** and antisense strand of **SEQ ID NO:131**;
sense strand of **SEQ ID NO:132** and antisense strand of **SEQ ID NO:133**;
sense strand of **SEQ ID NO:134** and antisense strand of **SEQ ID NO:135**;
sense strand of **SEQ ID NO:136** and antisense strand of **SEQ ID NO:137**;
sense strand of **SEQ ID NO:138** and antisense strand of **SEQ ID NO:139**;
sense strand of **SEQ ID NO:140** and antisense strand of **SEQ ID NO:141**;
sense strand of **SEQ ID NO:142** and antisense strand of **SEQ ID NO:143**;
sense strand of **SEQ ID NO:144** and antisense strand of **SEQ ID NO:145**;
sense strand of **SEQ ID NO:146** and antisense strand of **SEQ ID NO:147**;
sense strand of **SEQ ID NO:148** and antisense strand of **SEQ ID NO:149**;
sense strand of **SEQ ID NO:150** and antisense strand of **SEQ ID NO:151**;
sense strand of **SEQ ID NO:152** and antisense strand of **SEQ ID NO:153**;
sense strand of **SEQ ID NO:154** and antisense strand of **SEQ ID NO:155**;
sense strand of **SEQ ID NO:156** and antisense strand of **SEQ ID NO:157**; or
sense strand of **SEQ ID NO:158** and antisense strand of **SEQ ID NO:159**.

[0146] In some embodiments, the siRNA comprises, consists essentially of, or consists of a sequence at least 90% identical to one of **SEQ ID NOS:128-159**, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

Table 1: Fully modified siRNA sequences

Strand	Sequence (5'-3')	SEQ ID NO
S	GAGCUUGUGGCGUAGGCAAGA	128
AS	UUGCCUACGCCACAAGCUCCA	129
S	GAGCUGAUGGCGUAGGCAAGA	130
AS	UUGCCUACGCCAUCAGCUCCA	131
S	GAGCUGGUGACGUAGGCAAGA	132
AS	UUGCCUACGUCACCAGCUCCA	133
S	AGUUGGAGCUUGUGGCGUAGG	134
AS	UACGCCACAAGCUCCAACUAC	135
S	AGUUGGAGCUGAUGGCGUAGG	136
AS	UACGCCAUCAGCUCCAACUAC	137
S	AGUUGGAGCUGGUGACGUAGG	138
AS	UACGUCACCAGCUCCAACUAC	139
S	GGUAGUUGGAGCUGGUGACGU	140
AS	GUCACCAGCUCCAACUACCAC	141
S	AGUUGGAGCUGUUGGCGUAGG	142
AS	UACGCCAACAGCUCCAACUAC	143
S	GAGCUGUUGGCGUAGGCAAGA	144
AS	UUGCCUACGCCAACAGCUCCA	145
S	GAGCUGAUGGCGUAGGCAAGA	146
AS	UUGCCUACGCCAUCAGCUCCA	147
S	GAGCUGGUGACGUAGGCAAGA]	148
AS	UUGCCUACGUCACCAGCUCCA	149
S	AGUUGGAGCUUGUGGCGUAGG	150
AS	UACGCCACAAGCUCCAACUAC	151
S	AGUUGGAGCUGAUGGCGUAGG	152
AS	UACGCCAUCAGCUCCAACUAC	153
S	AGUUGGAGCUGGUGACGUAGG	154

AS	UACGUCACCAGCUCCAACUAC	155
S	AGUUGGAGCUGUUGGCGUAGG	156
AS	UACGCCAACAGCUCCAACUAC	157
S	GAGCUGUUGGCGUAGGCAAGA	158
AS	UUGCCUACGCCAACAGCACCA	159

S – sense strand

AS – antisense strand

[0147] In certain embodiments, the siRNA molecule is fully chemically modified and comprises a sense strand and an antisense strand, wherein the siRNA molecule comprises one of the following pairs of sequences:

sense strand of **SEQ ID NO:78** and antisense strand of **SEQ ID NO:79**;
 sense strand of **SEQ ID NO:80** and antisense strand of **SEQ ID NO:81**;
 sense strand of **SEQ ID NO:82** and antisense strand of **SEQ ID NO:83**;
 sense strand of **SEQ ID NO:84** and antisense strand of **SEQ ID NO:85**;
 sense strand of **SEQ ID NO:86** and antisense strand of **SEQ ID NO:87**;
 sense strand of **SEQ ID NO:88** and antisense strand of **SEQ ID NO:89**;
 sense strand of **SEQ ID NO:90** and antisense strand of **SEQ ID NO:91**;
 sense strand of **SEQ ID NO:92** and antisense strand of **SEQ ID NO:93**;
 sense strand of **SEQ ID NO:94** and antisense strand of **SEQ ID NO:95**;
 sense strand of **SEQ ID NO:96** and antisense strand of **SEQ ID NO:97**;
 sense strand of **SEQ ID NO:98** and antisense strand of **SEQ ID NO:99**;
 sense strand of **SEQ ID NO:100** and antisense strand of **SEQ ID NO:101**;
 sense strand of **SEQ ID NO:102** and antisense strand of **SEQ ID NO:103**;
 sense strand of **SEQ ID NO:104** and antisense strand of **SEQ ID NO:105**;
 sense strand of **SEQ ID NO:106** and antisense strand of **SEQ ID NO:107**;
 sense strand of **SEQ ID NO:108** and antisense strand of **SEQ ID NO:109**;
 sense strand of **SEQ ID NO:162** and antisense strand of **SEQ ID NO:163**;
 sense strand of **SEQ ID NO:164** and antisense strand of **SEQ ID NO:165**;
 sense strand of **SEQ ID NO:166** and antisense strand of **SEQ ID NO:167**;
 sense strand of **SEQ ID NO:168** and antisense strand of **SEQ ID NO:169**;
 sense strand of **SEQ ID NO:170** and antisense strand of **SEQ ID NO:171**;
 sense strand of **SEQ ID NO:172** and antisense strand of **SEQ ID NO:173**;
 sense strand of **SEQ ID NO:174** and antisense strand of **SEQ ID NO:175**;

sense strand of **SEQ ID NO:176** and antisense strand of **SEQ ID NO:177**;
sense strand of **SEQ ID NO:178** and antisense strand of **SEQ ID NO:179**;
sense strand of **SEQ ID NO:180** and antisense strand of **SEQ ID NO:181**;
sense strand of **SEQ ID NO:182** and antisense strand of **SEQ ID NO:183**; or
sense strand of **SEQ ID NO:184** and antisense strand of **SEQ ID NO:185**.

[0148] In some embodiments, the siRNA comprises, consists essentially of, or consists of a sequence at least 90% identical to one of **SEQ ID NOS:78-109 or 162-185**, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

[0149] Another aspect of the invention relates to an siRNA molecule targeted to human KRAS mRNA, wherein the sense strand of the siRNA comprises, consists essentially of, or consists of the sequence of **SEQ ID NO:50** or **SEQ ID NO:51**, and wherein the siRNA comprises at least one non-naturally occurring chemical modification. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the nucleotides in the siRNA are chemically modified. In some embodiments, the siRNA is fully chemically-modified. In some embodiments, each nucleotide in the siRNA molecule is modified with a 2'-O-methyl group or a 2'-fluoro group.

[0150] In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the nucleotide linkages in the siRNA are chemically modified. In some embodiments, the siRNA comprises at least one phosphorothioate linkage. In some embodiments, the siRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 phosphorothioate linkages. In some embodiments, the siRNA comprises all phosphorothioate linkages.

[0151] In certain embodiments, the fully chemically-modified siRNA molecule comprises a sense strand and an antisense strand, wherein the siRNA molecule comprises one of the following pairs of sequences:

sense strand of **SEQ ID NO:110** and antisense strand of **SEQ ID NO:111**; or
sense strand of **SEQ ID NO:112** and antisense strand of **SEQ ID NO:113**.

[0152] In some embodiments, the siRNA comprises, consists essentially of, or consists of a sequence at least 90% identical to one of **SEQ ID NOS:110-113**, *e.g.*, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical.

[0153] The double stranded RNA molecule, ASO, or chemically-modified siRNA molecule may be constructed using chemical synthesis and enzymatic ligation reactions by procedures known in the art. For example, a double stranded RNA, ASO, or chemically-modified siRNA molecule may be chemically synthesized using naturally occurring nucleotides or various modified nucleotides designed to increase the biological stability of the molecules or

to increase the physical stability of the duplex formed between the double stranded RNA, ASO, or chemically-modified siRNA molecule and target nucleotide sequences, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the double stranded RNA, ASO, or chemically-modified siRNA molecule include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the double stranded RNA or ASO can be produced using an expression vector into which a nucleic acid encoding the double stranded RNA or ASO has been cloned.

[0154] The double stranded RNA, ASO, or chemically-modified siRNA molecule can further include nucleotide sequences wherein at least one, or all, of the internucleotide bridging phosphate residues are modified phosphates, such as methyl phosphonates, methyl phosphonothioates, phosphoromorpholidates, phosphoropiperazidates and phosphoramidates. For example, every one or every other one of the internucleotide bridging phosphate residues can be modified as described. In another non-limiting example, the double stranded RNA, ASO, or chemically-modified siRNA molecule is a nucleotide sequence in which at least one, or all, of the nucleotides contain a 2' lower alkyl moiety (*e.g.*, C₁-C₄, linear or branched, saturated or unsaturated alkyl, such as methyl, ethyl, ethenyl, propyl, 1-propenyl, 2-propenyl, and isopropyl). In another example, one or more of the nucleotides may be a 2'-fluoro nucleotide, a 2'-O-methyl nucleotide, or a locked nucleic acid nucleotide. For example, every one or every other one of the nucleotides can be modified as described. *See also*, Furdon *et al.*, *Nucleic Acids Res.* 17:9193 (1989); Agrawal *et al.*, *Proc. Natl. Acad. Sci. USA* 87:1401 (1990); Baker *et al.*, *Nucleic Acids Res.* 18:3537 (1990); Sproat *et al.*, *Nucleic Acids Res.* 17:3373 (1989); Walder and Walder, *Proc. Natl. Acad. Sci. USA* 85:5011 (1988);

incorporated by reference herein in their entireties for their teaching of methods of making polynucleotide molecules, including those containing modified nucleotide bases).

[0155] The invention further relates to a nucleic acid construct comprising the RNA molecule or ASO of the invention. The invention further relates to a nucleic acid construct encoding the RNA molecule or ASO of the invention and a nucleic acid construct comprising the nucleic acid molecule encoding the RNA molecule or ASO. In each of these embodiments, the nucleic acid construct may be a vector or a plasmid, *e.g.*, an expression vector.

[0156] Another aspect of the invention relates to a composition comprising the RNA molecule, ASO, chemically-modified siRNA molecule, or nucleic acid construct of the invention and another component, *e.g.*, a suitable carrier. In some embodiments, the composition comprises two or more of the RNA molecules, ASOs, chemically-modified siRNA molecules, or nucleic acid constructs of the invention, wherein the two or more RNA molecules, ASO, or chemically-modified siRNA molecule each comprise a different antisense strand. In certain embodiments, the two or more RNA molecules are present on the same nucleic acid construct, on different nucleic acid constructs or any combination thereof. In some embodiments, the composition is a pharmaceutical composition comprising the RNA molecule(s), ASO(s), chemically-modified siRNA molecule(s), or nucleic acid construct(s) of the invention and a pharmaceutically acceptable carrier.

[0157] It is understood that the compositions of this invention can comprise, consist essentially of, or consist of any of the RNA molecules, ASOs, chemically-modified siRNA molecules, and nucleic acid constructs in any combination and in any ratio relative to one another. Furthermore, by “two or more” is meant 2, 3, 4, 5, 6, 7, 8, 9, 10, *etc.*, up to a total number of RNA molecules, ASOs, chemically-modified siRNA molecules, and nucleic acid constructs of this invention. In some embodiments, the compositions comprise, consist essentially of or consist of the RNA molecules of **SEQ ID NO:1** and **SEQ ID NO:3**.

[0158] In some aspects of the invention, the composition or pharmaceutical composition further comprises additional components that enhance the delivery of the RNA molecule(s), ASO(s), chemically-modified siRNA molecule(s), or nucleic acid construct(s) of the invention to a subject, *e.g.*, by enhancing the stability of the RNA molecule(s), ASO(s), chemically-modified siRNA molecule(s), or nucleic acid construct(s). In some embodiments, the additional component may be a particle, *e.g.*, a microparticle or nanoparticle. In some embodiments, the particle is a lipid particle, *e.g.*, a liposome, *e.g.*, a microliposome or a nanoliposome. The liposome, microliposome, or nanoliposome may contain any components

known in the art to be suitable for preparing liposomes. In some embodiments, the liposome comprises 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC). Liposomes may be prepared by methods known in the art, *e.g.*, as described in Pecot *et al.*, *Mol. Cancer Ther.* 13:2876 (2014), incorporated by reference herein in its entirety. In some embodiments, the RNA molecule is formed into a stable nucleic acid lipid particle (SNALP), *e.g.*, using particles such as those provided by Arbutus Biopharma (Doylestown, PA). In certain embodiments, the lipid particle comprises, consists essentially of, or consists of cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), PEG-cDMA or PEG-cDSA, and 1,2-dilinoleyloxy-3-(*N,N*-dimethyl)aminopropane (DLinDMA) (see Judge *et al.*, *J. Clin. Invest.* 119:661 (2009)). In some embodiments, the lipid particle comprises two or more of the RNA molecules, ASOs, or chemically-modified siRNA molecules of the invention, *e.g.*, the RNA molecules of **SEQ ID NO:1** and **SEQ ID NO:3**. In some embodiments, the additional component is a targeted delivery moiety to which the RNA molecule(s), ASO(s), chemically-modified siRNA molecule(s), or nucleic acid construct(s) or covalently or noncovalently conjugated, *e.g.*, ligands, aptamers, or monoclonal antibodies.

[0159] The present invention encompasses cells comprising the RNA molecules and/or nucleic acid constructs of the invention. Thus, in some embodiments, the present invention provides a transformed cell comprising a RNA molecule and/or a nucleic acid construct and/or a composition of this invention, wherein the transformed cell has reduced expression of mutant KRAS as compared to a control cell.

Methods

[0160] Various methods are provided herein, employing the nucleic acid molecules, nucleic acid constructs, and/or compositions of this invention. Thus, in one aspect, the present invention provides a method of inhibiting expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D in a cell, the method comprising contacting the cell with the RNA molecule, ASO, chemically-modified siRNA molecule, nucleic acid construct, composition, and/or pharmaceutical composition of the invention, thereby inhibiting expression of the mutant human KRAS gene in the cell.

[0161] Also provided herein is a method of treating cancer in a subject in need thereof, wherein the cancer comprises a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D, the method comprising delivering to the subject the RNA molecule, ASO, chemically-modified siRNA molecule, nucleic acid

construct, composition, and/or pharmaceutical composition of the invention, thereby treating cancer in the subject. A cancer comprising a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D is a cancer, *e.g.*, a tumor in which one or more cells express the mutant KRAS gene.

[0162] In one embodiment of each of these aspects, the subject may be one that has been diagnosed with cancer. In another embodiment, the subject may be one that is at risk of developing cancer (*e.g.*, predisposed due to hereditary factors, smoking, viral infection, exposure to chemicals, *etc.*). In a further embodiment, the subject may be one that has been identified as carrying a mutant KRAS gene and has or has not been diagnosed with cancer.

[0163] The double stranded RNA, ASO, or chemically-modified siRNA molecule of the invention can be delivered directly into a cell by any method known in the art, *e.g.*, by transfection or microinjection, *e.g.*, as part of a composition comprising lipid particles. In other embodiments, the double stranded RNA or ASO can be delivered to a subject in the form of polynucleotides encoding the RNA or ASO to produce expression of the double stranded RNA or ASO within the cells of the subject. Those skilled in the art will appreciate that the isolated polynucleotides encoding the RNAs or ASOs of the invention will typically be associated with appropriate expression control sequences, *e.g.*, transcription/translation control signals and polyadenylation signals.

[0164] It will further be appreciated that a variety of promoter/enhancer elements can be used depending on the level and tissue-specific expression desired. The promoter can be constitutive or inducible, depending on the pattern of expression desired. The promoter can be native or foreign and can be a natural or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced. The promoter is chosen so that it will function in the target cell(s) of interest.

[0165] To illustrate, the RNA or ASO coding sequence can be operatively associated with a cytomegalovirus (CMV) major immediate-early promoter, an albumin promoter, an Elongation Factor 1- α (EF1- α) promoter, a PyK promoter, a MFG promoter, or a Rous sarcoma virus promoter.

[0166] Inducible promoter/enhancer elements include hormone-inducible and metal-inducible elements, and other promoters regulated by exogenously supplied compounds, including without limitation, the zinc-inducible metallothionein (MT) promoter; the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter; the T7

polymerase promoter system (*see* WO 98/10088); the ecdysone insect promoter (No *et al.*, *Proc. Natl. Acad. Sci. USA* 93:3346 (1996)); the tetracycline-repressible system (Gossen *et al.*, *Proc. Natl. Acad. Sci. USA* 89:5547 (1992)); the tetracycline-inducible system (Gossen *et al.*, *Science* 268:1766 (1995); *see also* Harvey *et al.*, *Curr. Opin. Chem. Biol.* 2:512 (1998)); the RU486-inducible system (Wang *et al.*, *Nat. Biotech.* 15:239 (1997); Wang *et al.*, *Gene Ther.*, 4:432 (1997)); and the rapamycin-inducible system (Magari *et al.*, *J. Clin. Invest.* 100:2865 (1997)).

[0167] Other tissue-specific promoters or regulatory promoters include, but are not limited to, promoters that typically confer tissue-specificity in neurons. These include, but are not limited to, promoters for synapsin 1, tubulin α 1, platelet-derived growth factor B-chain, tyrosine hydroxylase, neuron-specific enolase, and neurofilaments. Skeletal muscle cell promoters include, but are not limited to, promoters for β -actin, Pitx3, creatine kinase, and myosin light chain. Cardiac muscle cell promoters include, but are not limited to, promoters for cardiac actin, cardiac troponin T, troponin C, myosin light chain-2, and α -myosin heavy chain. Islet (beta) cell promoters include, but are not limited to, glucokinase, gastrin, insulin, and islet amyloid polypeptide.

[0168] Moreover, specific initiation signals are generally required for efficient translation of inserted RNA or ASO coding sequences. These translational control sequences, which can include the ATG initiation codon and adjacent sequences, can be of a variety of origins, both natural and synthetic.

[0169] The isolated nucleic acid encoding the double stranded RNA or ASO can be incorporated into an expression vector. Expression vectors compatible with various host cells are well known in the art and contain suitable elements for transcription and translation of nucleic acids. Typically, an expression vector contains an "expression cassette," which includes, in the 5' to 3' direction, a promoter, a coding sequence encoding a double stranded RNA operatively associated with the promoter, and, optionally, a termination sequence including a stop signal for RNA polymerase and a polyadenylation signal for polyadenylase.

[0170] Non-limiting examples of animal and mammalian promoters known in the art include, but are not limited to, the SV40 early (SV40e) promoter region, the promoter contained in the 3' long terminal repeat (LTR) of Rous sarcoma virus (RSV), the promoters of the E1A or major late promoter (MLP) genes of adenoviruses (Ad), the cytomegalovirus (CMV) early promoter, the herpes simplex virus (HSV) thymidine kinase (TK) promoter, baculovirus IE1 promoter, elongation factor 1 alpha (EF1) promoter, phosphoglycerate kinase (PGK) promoter, ubiquitin (Ubc) promoter, an albumin promoter, the regulatory sequences of

the mouse metallothionein-L promoter and transcriptional control regions, the ubiquitous promoters (HPRT, vimentin, α -actin, tubulin and the like), the promoters of the intermediate filaments (desmin, neurofilaments, keratin, GFAP, and the like), the promoters of therapeutic genes (of the MDR, CFTR or factor VIII type, and the like), and pathogenesis and/or disease-related promoters. In addition, any of these expression sequences of this invention can be modified by addition of enhancer and/or regulatory sequences and the like.

[0171] Enhancers that may be used in embodiments of the invention include but are not limited to an SV40 enhancer, a cytomegalovirus (CMV) enhancer, an elongation factor I (EF1) enhancer, yeast enhancers, viral gene enhancers, and the like.

[0172] Termination control regions, *i.e.*, terminator or polyadenylation sequences, may be derived from various genes native to the preferred hosts. In some embodiments of the invention, the termination control region may comprise or be derived from a synthetic sequence, a synthetic polyadenylation signal, an SV40 late polyadenylation signal, an SV40 polyadenylation signal, a bovine growth hormone (BGH) polyadenylation signal, viral terminator sequences, or the like.

[0173] It will be apparent to those skilled in the art that any suitable vector can be used to deliver the polynucleotide to a cell or subject. The vector can be delivered to cells *in vivo*. In other embodiments, the vector can be delivered to cells *ex vivo*, and then cells containing the vector are delivered to the subject. The choice of delivery vector can be made based on a number of factors known in the art, including age and species of the target host, *in vitro* versus *in vivo* delivery, level and persistence of expression desired, intended purpose (*e.g.*, for therapy or screening), the target cell or organ, route of delivery, size of the isolated polynucleotide, safety concerns, and the like.

[0174] Suitable vectors include, but are not limited to, plasmid vectors, viral vectors (*e.g.*, retrovirus, alphavirus; vaccinia virus; adenovirus, adeno-associated virus and other parvoviruses, lentivirus, poxvirus, or herpes simplex virus), lipid vectors, poly-lysine vectors, synthetic polyamino polymer vectors, and the like.

[0175] Any viral vector that is known in the art can be used in the present invention. Protocols for producing recombinant viral vectors and for using viral vectors for nucleic acid delivery can be found in Ausubel *et al.*, *Current Protocols in Molecular Biology* (Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York) and other standard laboratory manuals (*e.g.*, *Vectors for Gene Therapy*. In: *Current Protocols in Human Genetics*. John Wiley and Sons, Inc.: 1997).

[0176] Non-viral transfer methods can also be employed. Many non-viral methods of nucleic acid transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In particular embodiments, non-viral nucleic acid delivery systems rely on endocytic pathways for the uptake of the nucleic acid molecule by the targeted cell. Exemplary nucleic acid delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.

[0177] In particular embodiments, plasmid vectors are used in the practice of the present invention. For example, naked plasmids can be introduced into muscle cells by injection into the tissue. Expression can extend over many months, although the number of positive cells is typically low (Wolff *et al.*, *Science* 247:247 (1989)). Cationic lipids have been demonstrated to aid in introduction of nucleic acids into some cells in culture (Felgner and Ringold, *Nature* 337:387 (1989)). Injection of cationic lipid plasmid DNA complexes into the circulation of mice has been shown to result in expression of the DNA in lung (Brigham *et al.*, *Am. J. Med. Sci.* 298:278 (1989)). One advantage of plasmid DNA is that it can be introduced into non-replicating cells.

[0178] In a representative embodiment, a nucleic acid molecule (*e.g.*, a plasmid) can be entrapped in a lipid particle bearing positive charges on its surface and, optionally, tagged with antibodies against cell surface antigens of the target tissue (Mizuno *et al.*, *No Shinkei Geka* 20:547 (1992); PCT publication WO 91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).

[0179] Liposomes that consist of amphiphilic cationic molecules are useful as non-viral vectors for nucleic acid delivery *in vitro* and *in vivo* (reviewed in Crystal, *Science* 270:404 (1995); Blaese *et al.*, *Cancer Gene Ther.* 2:291 (1995); Behr *et al.*, *Bioconjugate Chem.* 5:382 (1994); Remy *et al.*, *Bioconjugate Chem.* 5:647 (1994); and Gao *et al.*, *Gene Therapy* 2:710 (1995)). The positively charged liposomes are believed to complex with negatively charged nucleic acids via electrostatic interactions to form lipid:nucleic acid complexes. The lipid:nucleic acid complexes have several advantages as nucleic acid transfer vectors. Unlike viral vectors, the lipid:nucleic acid complexes can be used to transfer expression cassettes of essentially unlimited size. Since the complexes lack proteins, they can evoke fewer immunogenic and inflammatory responses. Moreover, they cannot replicate or recombine to form an infectious agent and have low integration frequency. A number of publications have demonstrated that amphiphilic cationic lipids can mediate nucleic acid delivery *in vivo* and *in vitro* (Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84:7413 (1987); Loeffler *et al.*, *Meth. Enzymol.* 217:599 (1993); Felgner *et al.*, *J. Biol. Chem.* 269:2550 (1994)).

[0180] Several groups have reported the use of amphiphilic cationic lipid:nucleic acid complexes for *in vivo* transfection both in animals and in humans (reviewed in Gao *et al.*, *Gene Therapy* 2:710 (1995); Zhu *et al.*, *Science* 261:209 (1993); and Thierry *et al.*, *Proc. Natl. Acad. Sci. USA* 92:9742 (1995)). U.S. Patent No. 6,410,049 describes a method of preparing cationic lipid:nucleic acid complexes that have a prolonged shelf life.

[0181] Nuclear localization signals can also be used to enhance the targeting of the double stranded RNA or expression vector into the proximity of the nucleus and/or its entry into the nucleus. Such nuclear localization signals can be a protein or a peptide such as the SV40 large Tag NLS or the nucleoplasmin NLS. These nuclear localization signals interact with a variety of nuclear transport factors such as the NLS receptor (karyopherin alpha) which then interacts with karyopherin beta.

[0182] Expression vectors can be designed for expression of stranded RNA or ASOs in prokaryotic or eukaryotic cells. For example, stranded RNA or ASOs can be expressed in bacterial cells such as *E. coli*, insect cells (*e.g.*, the baculovirus expression system), yeast cells, plant cells or mammalian cells. Some suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990). Examples of bacterial vectors include, but are not limited to, pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia). Examples of vectors for expression in the yeast *S. cerevisiae* include pYepSecl (Baldari *et al.*, *EMBO J.* 6:229 (1987)), pMFa (Kurjan and Herskowitz, *Cell* 30:933 (1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Non-limiting examples of baculovirus vectors available for expression of nucleic acids to produce proteins in cultured insect cells (*e.g.*, Sf9 cells) include the pAc series (Smith *et al.*, *Mol. Cell. Biol.* 3:2156 (1983)) and the pVL series (Lucklow and Summers *Virology* 170:31 (1989)).

[0183] Examples of mammalian expression vectors include pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, PBPV, pMSG, PSVL (Pharmacia), pCDM8 (Seed, *Nature* 329:840 (1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187 (1987)). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus and Simian Virus 40.

[0184] Viral vectors have been used in a wide variety of gene delivery applications in cells, as well as living animal subjects. Viral vectors that can be used include, but are not limited

to, retrovirus, lentivirus, adeno-associated virus, poxvirus, alphavirus, baculovirus, vaccinia virus, herpes virus, Epstein-Barr virus, adenovirus, geminivirus, and caulimovirus vectors. Non-limiting examples of non-viral vectors include plasmids, liposomes, electrically charged lipids (cytofectins), nucleic acid-protein complexes, and biopolymers. In addition to a nucleic acid of interest, a vector may also comprise one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (delivery to specific tissues, duration of expression, *etc.*).

[0185] In addition to the regulatory control sequences discussed above, the recombinant expression vector can contain additional nucleotide sequences. For example, the recombinant expression vector can encode a selectable marker gene to identify host cells that have incorporated the vector.

[0186] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” refer to a variety of art-recognized techniques for introducing foreign nucleic acids (*e.g.*, DNA and RNA) into a host cell, including, but are not limited to, calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection, DNA-loaded liposomes, lipofectamine-DNA complexes, cell sonication, gene bombardment using high velocity microprojectiles, and viral-mediated transfection. Suitable methods for transforming or transfecting host cells can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* 2nd Ed. (Cold Spring Harbor, NY, 1989), and other laboratory manuals.

[0187] If stable integration is desired, often only a small fraction of cells (in particular, mammalian cells) integrate the foreign DNA into their genome. In order to identify and select integrants, a nucleic acid that encodes a selectable marker (*e.g.*, resistance to antibiotics) can be introduced into the host cells along with the nucleic acid of interest. Preferred selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acids encoding a selectable marker can be introduced into a host cell on the same vector as that comprising the nucleic acid of interest or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0188] In one embodiment, the double stranded RNA, ASO, or chemically-modified siRNA molecule of the invention is administered directly to the subject. Generally, the compounds of the invention will be suspended in a pharmaceutically-acceptable carrier (*e.g.*,

physiological saline) and administered orally, topically, or by intravenous infusion, or injected subcutaneously, intramuscularly, intracranially, intrathecally, intraperitoneally, intrarectally, intravaginally, intranasally, intragastrically, intratracheally, or intrapulmonarily. They are preferably delivered directly to the site of the disease or disorder, such as the lung, intestine, or pancreas. The dosage required depends on the choice of the route of administration; the nature of the formulation; the nature of the patient's illness; the subject's size, weight, surface area, age, and sex; other drugs being administered; and the judgment of the attending physician. Suitable dosages are in the range of 0.01-100.0 µg/kg. Wide variations in the needed dosage are to be expected in view of the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by i.v. injection (e.g., 2-, 3-, 4-, 6-, 8-, 10-, 20-, 50-, 100-, 150-, or more fold). Variations in these dosage levels can be adjusted using standard empirical routines for optimization as is well understood in the art. Administrations can be single or multiple. Encapsulation of the inhibitor in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery, particularly for oral delivery.

[0189] According to certain embodiments, the double stranded RNA, ASO, or chemically-modified siRNA molecule can be targeted to specific cells or tissues *in vivo*. Targeting delivery vehicles, including liposomes and viral vector systems are known in the art. For example, a liposome can be directed to a particular target cell or tissue by using a targeting agent, such as an antibody, soluble receptor or ligand, incorporated with the liposome, to target a particular cell or tissue to which the targeting molecule can bind. Targeting liposomes are described, for example, in Ho *et al.*, *Biochemistry* 25:5500 (1986); Ho *et al.*, *J. Biol. Chem.* 262:13979 (1987); Ho *et al.*, *J. Biol. Chem.* 262:13973 (1987); and U.S. Pat. No. 4,957,735 to Huang *et al.*, each of which is incorporated herein by reference in its entirety). Enveloped viral vectors can be modified to deliver a nucleic acid molecule to a target cell by modifying or substituting an envelope protein such that the virus infects a specific cell type. In adenoviral vectors, the gene encoding the attachment fibers can be modified to encode a protein domain that binds to a cell-specific receptor. Herpesvirus vectors naturally target the cells of the central and peripheral nervous system. Alternatively, the route of administration can be used to target a specific cell or tissue. For example, intracoronary administration of an adenoviral vector has been shown to be effective for the delivery of a gene to cardiac myocytes (Maurice *et al.*, *J. Clin. Invest.* 104:21 (1999)). Intravenous delivery of cholesterol-containing cationic liposomes has been shown to preferentially target pulmonary

tissues (Liu *et al.*, *Nature Biotechnol.* 15:167 (1997)), and effectively mediate transfer and expression of genes *in vivo*. Other examples of successful targeted *in vivo* delivery of nucleic acid molecules are known in the art. Finally, a recombinant nucleic acid molecule can be selectively (*i.e.*, preferentially, substantially exclusively) expressed in a target cell by selecting a transcription control sequence, and preferably, a promoter, which is selectively induced in the target cell and remains substantially inactive in non-target cells.

[0190] The double stranded RNA, ASO, or chemically-modified siRNA molecule of the present invention can optionally be delivered in conjunction with other therapeutic agents. The additional therapeutic agents can be delivered concurrently with the double stranded RNA, ASO, or chemically-modified siRNA molecule of the invention. As used herein, the word “concurrently” means sufficiently close in time to produce a combined effect (that is, concurrently can be simultaneously, or it can be two or more events occurring within a short time period before or after each other). In one embodiment, the double stranded RNA, ASO, or chemically-modified siRNA molecule of the invention are administered in conjunction with agents useful for treating cancer, such as: 1) vinca alkaloids (*e.g.*, vinblastine, vincristine); 2) epipodophyllotoxins (*e.g.*, etoposide and teniposide); 3) antibiotics (*e.g.*, dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes (*e.g.*, L-asparaginase); 5) biological response modifiers (*e.g.*, interferon- α); 6) platinum coordinating complexes (*e.g.*, cisplatin and carboplatin); 7) anthracenediones (*e.g.*, mitoxantrone); 8) substituted ureas (*e.g.*, hydroxyurea); 9) methylhydrazine derivatives (*e.g.*, procarbazine (N-methylhydrazine; MIH)); 10) adrenocortical suppressants (*e.g.*, mitotane (o,p'-DDD) and aminoglutethimide); 11) adrenocorticosteroids (*e.g.*, prednisone); 12) progestins (*e.g.*, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate); 13) estrogens (*e.g.*, diethylstilbestrol and ethinyl estradiol); 14) antiestrogens (*e.g.*, tamoxifen); 15) androgens (*e.g.*, testosterone propionate and fluoxymesterone); 16) antiandrogens (*e.g.*, flutamide); and 17) gonadotropin-releasing hormone analogs (*e.g.*, leuprolide). In another embodiment, the compounds of the invention are administered in conjunction with anti-angiogenesis agents, such as antibodies to VEGF (*e.g.*, bevacizumab (AVASTIN), ranibizumab (LUCENTIS)) and other promoters of angiogenesis (*e.g.*, bFGF, angiopoietin-1), antibodies to α -v/ β -3 vascular integrin (*e.g.*, VITAXIN), angiostatin, endostatin, dalteparin, ABT-510, CNGRC peptide TNF α conjugate, cyclophosphamide, combretastatin A4 phosphate, dimethylxanthenone acetic acid, docetaxel, lenalidomide, enzastaurin, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation (Abraxane),

soy isoflavone (Genistein), tamoxifen citrate, thalidomide, ADH-1 (EXHERIN), AG-013736, AMG-706, AZD2171, sorafenib tosylate, BMS-582664, CHIR-265, pazopanib, PI-88, vatalanib, everolimus, suramin, sunitinib malate, XL184, ZD6474, ATN-161, cilenigtide, and celecoxib, or any combination thereof.

[0191] The term “cancer,” as used herein, refers to any benign or malignant abnormal growth of cells. Examples include, without limitation, breast cancer, prostate cancer, lymphoma, skin cancer, pancreatic cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma. In some embodiments, the cancer is selected from the group of tumor-forming cancers.

Pharmaceutical compositions

[0192] As a further aspect, the invention provides pharmaceutical formulations and methods of administering the same to achieve any of the therapeutic effects (*e.g.*, treatment of cancer) discussed above. The pharmaceutical formulation may comprise any of the reagents discussed above in a pharmaceutically acceptable carrier.

[0193] By “pharmaceutically acceptable” it is meant a material that is not biologically or otherwise undesirable, *i.e.*, the material can be administered to a subject without causing any undesirable biological effects such as toxicity.

[0194] The formulations of the invention can optionally comprise medicinal agents, pharmaceutical agents, carriers, adjuvants, dispersing agents, diluents, and the like.

[0195] The double stranded RNA, ASO, chemically-modified siRNA molecule, or nucleic acid construct of the invention can be formulated for administration in a pharmaceutical carrier in accordance with known techniques. *See, e.g., Remington, The Science And Practice of Pharmacy* (9th Ed. 1995). In the manufacture of a pharmaceutical formulation according to the invention, the double stranded RNA, ASO, or chemically-modified siRNA molecule (including the physiologically acceptable salts thereof) is typically admixed with, *inter alia*, an acceptable carrier. The carrier can be a solid or a liquid, or both, and is preferably formulated with the double stranded RNA, ASO, or chemically-modified siRNA molecule as a unit-dose formulation, for example, a tablet, which can contain from 0.01 or 0.5% to 95% or 99% by weight of the double stranded RNA, ASO, or chemically-modified siRNA molecule. One or more double stranded RNAs, ASOs, or chemically-modified siRNA molecules can be incorporated in the formulations of the invention, which can be prepared by any of the well-known techniques of pharmacy.

[0196] A further aspect of the invention is a method of treating subjects *in vivo*, comprising administering to a subject a pharmaceutical composition comprising a double stranded RNA, ASO, or chemically-modified siRNA molecule of the invention in a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is administered in a therapeutically effective amount. Administration of the double stranded RNA, ASO, or chemically-modified siRNA molecule of the present invention to a human subject or an animal in need thereof can be by any means known in the art for administering compounds.

[0197] Non-limiting examples of formulations of the invention include those suitable for oral, rectal, buccal (*e.g.*, sub-lingual), vaginal, parenteral (*e.g.*, subcutaneous, intramuscular including skeletal muscle, cardiac muscle, diaphragm muscle and smooth muscle, intradermal, intravenous, intraperitoneal), topical (*i.e.*, both skin and mucosal surfaces, including airway surfaces), intranasal, transdermal, intraarticular, intracranial, intrathecal, and inhalation administration, administration to the liver by intraportal delivery, as well as direct organ injection (*e.g.*, into the liver, into a limb, into the brain or spinal cord for delivery to the central nervous system, into the pancreas, or into a tumor or the tissue surrounding a tumor). The most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular compound which is being used. In some embodiments, it may be desirable to deliver the formulation locally to avoid any side effects associated with systemic administration. For example, local administration can be accomplished by direct injection at the desired treatment site, by introduction intravenously at a site near a desired treatment site (*e.g.*, into a vessel that feeds a treatment site). In some

embodiments, the formulation can be delivered locally to ischemic tissue. In certain embodiments, the formulation can be a slow release formulation, *e.g.*, in the form of a slow release depot.

[0198] For injection, the carrier will typically be a liquid, such as sterile pyrogen-free water, pyrogen-free phosphate-buffered saline solution, bacteriostatic water, or Cremophor EL[R] (BASF, Parsippany, N.J.). For other methods of administration, the carrier can be either solid or liquid.

[0199] For oral administration, the compound can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. Compounds can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like. Examples of additional inactive ingredients that can be added to provide desirable color, taste, stability, buffering capacity, dispersion or other known desirable features are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

[0200] Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

[0201] Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations can contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions can include suspending agents and thickening agents. The formulations can be presented in unit/dose or multi-dose containers, for example sealed ampoules and vials, and can be stored

in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use.

[0202] Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the kind previously described. For example, in one aspect of the present invention, there is provided an injectable, stable, sterile composition comprising a compound of the invention, in a unit dosage form in a sealed container. The compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject. The unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt. When the compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent which is pharmaceutically acceptable can be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

[0203] Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These can be prepared by admixing the compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

[0204] Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

[0205] Formulations suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration can also be delivered by iontophoresis (*see*, for example, Tyle, *Pharm. Res.* 3:318 (1986)) and typically take the form of an optionally buffered aqueous solution of the compound. Suitable formulations comprise citrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M of the compound.

[0206] The compound can alternatively be formulated for nasal administration or otherwise administered to the lungs of a subject by any suitable means, *e.g.*, administered by an aerosol suspension of respirable particles comprising the compound, which the subject inhales. The respirable particles can be liquid or solid. The term "aerosol" includes any gas-borne suspended phase, which is capable of being inhaled into the bronchioles or nasal passages. Specifically, aerosol includes a gas-borne suspension of droplets, as can be produced in a metered dose inhaler or nebulizer, or in a mist sprayer. Aerosol also includes a dry powder

composition suspended in air or other carrier gas, which can be delivered by insufflation from an inhaler device, for example. *See Ganderton & Jones, Drug Delivery to the Respiratory Tract*, Ellis Horwood (1987); Gonda (1990) *Critical Reviews in Therapeutic Drug Carrier Systems* 6:273-313; and Raeburn *et al.*, *J. Pharmacol. Toxicol. Meth.* 27:143 (1992).

Aerosols of liquid particles comprising the compound can be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is known to those of skill in the art. *See, e.g.*, U.S. Patent No. 4,501,729. Aerosols of solid particles comprising the compound can likewise be produced with any solid particulate medicament aerosol generator, by techniques known in the pharmaceutical art.

[0207] Alternatively, one can administer the compound in a local rather than systemic manner, for example, in a depot or sustained-release formulation.

[0208] Further, the present invention provides liposomal formulations of the compounds disclosed herein and salts thereof. The technology for forming liposomal suspensions is well known in the art. When the compound or salt thereof is an aqueous-soluble salt, using conventional liposome technology, the same can be incorporated into lipid vesicles. In such an instance, due to the water solubility of the compound or salt, the compound or salt will be substantially entrained within the hydrophilic center or core of the liposomes. The lipid layer employed can be of any conventional composition and can either contain cholesterol or can be cholesterol-free. When the compound or salt of interest is water-insoluble, again employing conventional liposome formation technology, the salt can be substantially entrained within the hydrophobic lipid bilayer which forms the structure of the liposome. In either instance, the liposomes which are produced can be reduced in size, as through the use of standard sonication and homogenization techniques.

[0209] The liposomal formulations containing the compounds disclosed herein or salts thereof, can be lyophilized to produce a lyophilizate which can be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.

[0210] In the case of water-insoluble compounds, a pharmaceutical composition can be prepared containing the water-insoluble compound, such as for example, in an aqueous base emulsion. In such an instance, the composition will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the compound. Particularly useful emulsifying agents include phosphatidyl cholines and lecithin.

[0211] In particular embodiments, the compound is administered to the subject in a therapeutically effective amount, as that term is defined above. Dosages of pharmaceutically active compounds can be determined by methods known in the art, *see, e.g., Remington's*

Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa). The therapeutically effective dosage of any specific compound will vary somewhat from compound to compound, and patient to patient, and will depend upon the condition of the patient and the route of delivery. As a general proposition, a dosage from about 0.001 to about 50 mg/kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the compound, including the cases where a salt is employed. Toxicity concerns at the higher level can restrict intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon the weight of the compound, including the cases where a salt is employed. A dosage from about 10 mg/kg to about 50 mg/kg can be employed for oral administration. Typically, a dosage from about 0.5 mg/kg to 5 mg/kg can be employed for intramuscular injection. Particular dosages are about 1 $\mu\text{mol/kg}$ to 50 $\mu\text{mol/kg}$, and more particularly to about 22 $\mu\text{mol/kg}$ and to 33 $\mu\text{mol/kg}$ of the compound for intravenous or oral administration, respectively.

[0212] In particular embodiments of the invention, more than one administration (*e.g.*, two, three, four, or more administrations) can be employed over a variety of time intervals (*e.g.*, hourly, daily, weekly, monthly, *etc.*) to achieve therapeutic effects.

[0213] The present invention finds use in veterinary and medical applications. Suitable subjects include both avians and mammals, with mammals being preferred. The term “avian” as used herein includes, but is not limited to, chickens, ducks, geese, quail, turkeys, and pheasants. The term “mammal” as used herein includes, but is not limited to, humans, bovines, ovines, caprines, equines, felines, canines, lagomorphs, *etc.* Human subjects include neonates, infants, juveniles, and adults. In other embodiments, the subject is an animal model of cancer. In certain embodiments, the subject has or is at risk for cancer.

[0214] The following examples are not intended to limit the scope of the claims to the invention, but are rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods that occur to the skilled artisan are intended to fall within the scope of the present invention. As will be understood by one skilled in the art, there are several embodiments and elements for each aspect of the claimed invention, and all combinations of different elements are hereby anticipated, so the specific combinations exemplified herein are not to be construed as limitations in the scope of the invention as claimed. If specific elements are removed or added to the group of elements available in a combination, then the group of elements is to be construed as having incorporated such a change.

EXAMPLE 1

Mutant KRAS-Specific siRNAs

[0215] Methods: Novel mutant-specific siRNAs (MS siRNAs) were designed based on previous literature that suggests a 3-mismatch tolerance threshold for 19-nucleotide siRNA efficacy (Naito *et al.*, *Nucleic Acids Res.* 32:W124 (2004)). With two or fewer mismatches between the sequence and the target gene, the siRNA is able to successfully bind and knock-down expression of the gene of interest; however, at and above the 3 mismatch threshold, the siRNA fails to recognize the target, thus allowing for expression of the encoded protein. Custom MS siRNAs were generated using open source softwares provided by Sigma Aldrich, Life Technologies and Dharmacon to be antisense to an artificial, hyper-mutated version of the WT KRAS gene which never actually occurs in nature, with exactly 3 point mutations corresponding to each of the most commonly occurring KRAS mutants (G12C, G12D or G12V, and G13D). Thirty flanking nucleotides were included upstream and downstream of these sites in the artificial, hyper-mutated mRNA input (**FIG. 1**). Of note, siRNA sequences were designed to target two different artificial mRNA sequences; one that simultaneously contained specific missense mutations in codons 12 (G12C and G12D) and 13 (G13D), and another that simultaneously contained specific missense mutations in codons 12 (G12C and G12V) and 13 (G13D) (**FIG. 1**). The resultant sequence is thus antisense with 3 mismatch errors to WT KRAS but only 2 mismatch errors to each of the 3 mutant KRAS alleles. Consequently, it was hypothesized that these MS siRNAs will optimize the task of targeting mutant KRAS while sparing the WT KRAS allele since the sequence is below the 3 mismatch threshold for the former and above for the latter. In addition, by introducing one mutation from each of 3 different prevalent KRAS mutants in the custom sequence design, the resultant siRNA has the added potential benefit of simultaneously targeting several KRAS mutants rather than one.

[0216] Constructs containing the WT, G12C, G12D, G12V, or G13D KRAS gene inserted into pBABE-puro retroviral expression vectors were prepared. To expand the vector constructs, plasmids were added to high efficiency competent *E. coli* cells and incubated in S.O.C. media on a shaker at 37 °C. Cells were then plated on ampicillin agarose plates and incubated at 37 °C overnight. Liquid cultures were prepared by picking and placing bacterial colonies from the overnight plates into LB broth with 1 µl/ml carbocyclin and incubating overnight on a shaker at 37 °C. Liquid cultures were performed in triplicate. Plasmid DNA from the resultant turbid cultures was purified using a QIAprep Spin Miniprep Kit (Qiagen). Successful plasmid expansion was confirmed via restriction enzyme digest using BamHI and

HindIII and gel electrophoresis. Undigested plasmids from the Miniprep were further expanded in LB Broth with 0.1 µl/ml carbocyclin and then purified using a QIAprep Spin Maxiprep Kit (Qiagen).

[0217] To produce retrovirus containing the pBABE-puro-KRAS plasmids, 9×10^6 HEK 293T cells were seeded onto 6 cm cell culture plates in 293T media (DMEM with 10% FBS and 1% penicillin-streptomycin) and incubated at 37 °C, 5% CO₂. After 24 hours, plasmid DNA mixtures were prepared for each pBABE-puro-KRAS plasmid by creating a mixture of 0.01 µg/µl plasmid construct and 0.01 µg/µl PCL10A pack vector plasmid to OptiMEM media. In addition, a L2K mixture was prepared by adding 0.05 µg/µl Lipofectamine 2000 (Thermo Fisher Scientific) in OptiMEM media and incubating at room temperature for 5 minutes. The L2K mixture was then combined 1:1 with each plasmid DNA mixture and incubated at room temperature for 20 minutes. Media was removed from the incubated cells, then 2 ml of 293T media was added to each well along with 250 µl of the plasmid DNA/L2K mixture. After another 24 hours, the plasmid DNA/L2K media was replaced with 293T media. After another 24 hours, the resultant viral media was collected from the wells and replaced with fresh 293T media. Virus media was stored overnight on ice at 4 °C. After another 24 hours, media was collected again from the wells and added to the previously stored virus. The mixture was centrifuged at room temperature, then the supernatant was collected. This process was repeated using mCherry and 293T media instead of plasmid construct to produce mCherry and empty vector virus, respectively.

[0218] To infect cells with KRAS plasmid, NIH 3T3 cells were harvested and seeded at 100,000 per well in 6 well plates in complete media (DMEM with 10% Colorado calf serum and 1% pen/strep). After 4-6 hours and once the cells attached, the media was aspirated and 2 ml of complete media with 10 µl/ml polybrene along with 250 µl of viral media (WT, G12C, G12D, G12V, G13D, mCherry, and empty vector) or complete media (negative controls) were added to each well. Cells were centrifuged at 1500 g for 60 minutes at 30 °C, then incubated overnight at 37 °C. After 24 hours, wells were aspirated and complete media was added to each well. After another 24 hours, wells were aspirated and complete media with 2 µg/ml puromycin was added. Media was replaced with puromycin media every 24 hours until no living cells remained in the negative control wells. Successful infection was further verified using mCherry expression.

[0219] RNAi knockdown was induced in KRAS-infected NIH 3T3 cells plated at a density of 60,000 cells per 500 µl complete media per well in 24 well plates. Sequences for the scrambled control siRNA, as well as positive controls (Seq #2 and #3, G12C and G12D

siRNAs) previously found to potently silence wild-type and mutant KRAS were used as indicated in **Fig. 1** (Fleming *et al.*, *Mol. Cancer Res.* 3:413 (2005); Pecot *et al.*, *Mol. Cancer Ther.* 13:2876 (2014)). Cells were incubated in 5:1 mixture of complete media and serum-free media, along with 20 nM siRNA (Sigma Aldrich) and Lipofectamine(R) RNAiMAX transfection reagent (Thermo Fisher Scientific, 2:1 ratio of transfection reagent to siRNA by volume) for 5 hours at 37 °C in 5% CO₂. Media was removed, and cells were incubated in complete media only for another 19 hours before RNA was collected and purified using a QIAprep Spin Miniprep Kit.

[0220] Purified RNA from siRNA treatments was quantified using a spectrophotometer, then reverse transcribed to cDNA using an iScript™ cDNA Synthesis Kit (Bio-Rad). To quantify relative expression levels of KRAS, RT-PCR reactions were performed by monitoring real-time changes in fluorescent intensity of SYBR green on the StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific). Each sample was run in triple replicate. The StepOnePlus™ was also used to obtain RQ values using the $\Delta\Delta$ CT analysis to calculate Δ Ct values by comparing cycle threshold (Ct values) of KRAS to those of the target reference gene, 18s, then compare Δ Ct values for each siRNA to those of the NC siRNA. Error bars represent 1 standard deviation. Data represents the result of one trial of two biological replicates for WT and G12D and two trials of two biological replicates for G12C, G12V, and G13D. Reverse transfection experiments were performed in duplicate for each siRNA for each cell line.

[0221] Results: To test the efficacy of mutant-specific KRAS silencing in vitro, a panel of candidate MS KRAS siRNA sequences was tested for their ability to knock-down KRAS expression in both WT and target mutant KRAS-expressing cells. The 12CD13D_1 sequence was observed to exhibit a sparing of WT KRAS expression (only 4% knock-down compared to negative control siRNA) while knocking down G12C (50%), G12D (82%), and G13D mutant KRAS (66%) (**FIG. 2A**). The sequence was also unexpectedly noted to knock down G12V expression (58%). Additionally, 12CD13D_2 and 12CD13D_4 were also found to exhibit WT sparing and mutant knockdown. However, the former appeared to exhibit less WT sparing than 12CD13D_1 and the latter less KRAS knockdown in all cell lines (**FIG. 2A**). The remaining sequences exhibited either low potency against mutant KRAS, high KRAS knockdown in the WT KRAS cell line, or both (**FIG. 2A**).

[0222] In addition, G12C- and G12D-specific siRNA sequences (Fleming *et al.*, *Mol. Cancer Res.* 3:413 (2005)) were tested in order to compare the efficacy of MS siRNA sequences against those previously demonstrated to exhibit target-specificity. However, the

mutant-specificity of these sequences was not confirmed, and the sequences did not exhibit the expected preferential knockdown of G12C and G12D mutant KRAS, respectively, over the WT or other mutant alleles (**FIG. 2B**).

[0223] KRAS siRNA sequences 12CD13D_1 and 12CD13D_4 were tested in a KRAS G12D mutant lung cancer cell line. Using a control siRNA (Scr) and two previously validated KRAS siRNAs (Seq #2 and #3), it was demonstrated that customized, mutant specific KRAS siRNA sequences 12CD13D_1 and 12CD13D_4 are highly effective at silencing KRAS protein expression (**FIG. 3**).

[0224] Testing all possible siRNA sequence permutations between our custom siRNA sequences. In order to verify the best possible custom KRAS siRNA sequences (leading sequences being 12CD13D_1 and 12CD13D_4), a library of sequences (12CD13D_A thru 12CD13D_F) were tested that incrementally move downstream between 12CD13D_1 and 12CD13D_4 (**FIG. 4**).

[0225] Following stable transduction of 3T3 cells with either wild-type (WT) or mutant G12C, G12D, G12V and G13D human KRAS sequences, the cells were transfected with KRAS siRNA sequences listed in **FIG. 5**. Twenty-four hours after transfection, cells were lysed, RNA collected and cDNA was made. Quantitative qPCR was performed for KRAS using 18s as a house-keeping gene. It was found that the leading 12CD13D_1 and 12CD13D_4 custom sequences were still the best overall at silencing mutant KRAS, while the other possible KRAS siRNA sequences (“A” thru “F”) were less potent overall at silencing the different KRAS mRNA sequences. On this experiment the custom KRAS siRNA 12CD13D_4 sequence was best at sparing the WT sequence.

[0226] **Discussion:** Although numerous efforts have been made to target mutant KRAS, no direct inhibitors are currently in clinical use. Moreover, most current small-molecule cancer therapeutics exhibit low target specificity, resulting in adverse toxicity in non-cancerous cells (Pecot *et al.*, *Nat. Rev. Cancer* 11:59 (2011)). Despite current headways in inhibiting downstream effectors in the KRAS signaling pathway, KRAS remains an elusive target for drug development (Cox *et al.*, *Nat. Rev. Drug Discov.* 13:828 (2014)). As such, this study investigated the efficacy of novel MS siRNA as a means of selectively inhibiting expression of mutant KRAS.

[0227] Based on these preliminary findings, the 12CD13D_1 and 12CD13D_2 siRNA sequences were chosen as lead candidates for further investigation as therapeutic agents because of their high mutant-specificity and potency. To a lesser extent, 12CD13D_4 is also a promising candidate; however, its low efficiency in knocking down KRAS expression in

mutant targets suggests that it may not be effective as a clinically relevant therapeutic agent. By contrast, the G12C- and G12D-specific siRNA do not appear to exhibit any sort of sparing of the WT KRAS allele.

[0228] In addition, the low specificity of both sequences designed to target the G12V rather than the G12D point mutation suggests a greater tolerance for WT KRAS in G12V-targeting sequences.

[0229] These preliminary findings collectively suggest the viability of novel MS siRNAs as a mutant-specific vehicle for silencing oncogenic KRAS. With its potential as an effective payload with mutant KRAS specificity, novel mutant-specific siRNAs present a promising avenue of pursuit for drugging the formerly “undruggable.”

EXAMPLE 2

Antisense Oligonucleotides Targeted to Synthetic Mutant KRAS

[0230] A series of antisense oligonucleotide (ASO) sequences were created that target a mutant KRAS of the invention comprising the mutations G12C, G12D and G13D (SEQ ID NO:53) relative to the wild-type KRAS sequence (SEQ ID NO:52) (FIG. 6 and Table 2). In FIG. 6, the black bars represent nucleotides that have a 2'-methoxy-ethyl (MOE) modification, while the gray regions represent the “Gapmer” that is composed of DNA. The schematic is not to scale and the black bars are composed of 5 flanking MOE-modified nucleotides on each side while there is a 10 nucleotide Gapmer. The ASOs incorporate phosphorothioate linkages (PS, designated by a “*”) between all nucleotides, a 10-nt Gapmer (underlined), and 5 flanking 2'-MOE (methoxy-ethyl) modifications (bold). The ASOs were tested to identify single-stranded RNA and/or DNA sequences that maintain the ability to silence several KRAS mutations.

Table 2: ASO sequences

ASO Number	Sequence	SEQ ID NO
1	T *C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C*C*A*C	54
2	G *T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C*C*A	55
3	C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C*C	56
4	A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A*C	57
5	T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T*A	58
6	C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C*T	59

7	C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A*C	60
8	G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A*A	61
9	T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C*A	62
10	T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C*C	63
11	C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T*C	64
12	T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C*T	65
13	C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G*C	66
14	A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A*G	67
15	C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A	68
16	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A	69

[0231] Four separate A431 cell lines were engineered to remove expression of wild-type KRAS and express one of the mutations G12C, G12D, G13D, or G12V. Each cell line was treated with free ASOs at 1.1 μM for 48 hours, and qPCR was run. The results are shown in **FIG. 7**. While several of the ASOs were demonstrated to silence one or more of the mutations, it was found that ASO15 and ASO16 were very potent at silencing all 4 of the most common KRAS mutations.

[0232] Some of the top hits were re-evaluated, and again ASO15 and ASO16 were found to potently silence all 4 of the KRAS mutations in a dose-responsive manner (**FIG. 8**). Cells were treated with free ASOs at 1.1 μM and 10 μM for 48 hours, then qPCR was run for mutant KRAS.

EXAMPLE 3

Modified ASO16 Sequences

[0233] Starting with the potent ASO16, modified versions were prepared to identify ASOs with increased mutation specificity by targeting the ASO to mutations that exist in nature, e.g., single mutations (G12C, G12D, G12V, or G13D). Modifications included base substitutions and the use of locked nucleic acids. The modified sequences are shown in **Table 3**. The ASOs incorporate phosphorothioate linkages (PS, designated by a “*”) between all nucleotides, a 10-nt Gapmer (underlined), and 5 flanking 2'-MOE (methoxy-ethyl) modifications (bold). The last four sequences use a single locked nucleic acid (LNA, denoted by “+” before the base) in place of an MOE to increase melting temperatures at specific sites. The LNA consists of a methylene bridge connecting the 2' and 4' carbons.

Table 3: Modified ASO16 sequences

ASO Number	Sequence	SEQ ID NO
16	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A	69
ASO16-G12C	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*A	70
ASO16-G12D	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*T*C	71
ASO16-G12V	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*A*C	72
ASO16-G13D	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*C*C	73
ASO16-G12C-LNA (ASO16-G12C-L)	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*+A	74
ASO16-G12D-LNA	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+T*C	75
ASO16-G12V-LNA	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+A*C	76
ASO16-G13D-LNA	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*+T*C*A*C*C	77
ASO16-G12C-LL	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*+C*+A	160
ASO16-G12C-LLL	G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*+A*+C*+A	161

[0234] The ASOs were tested on the A431 cell lines as described above. The results are shown in **FIG. 9**. Improved potency for each KRAS mutation was found for: 1) G12C using ASO16-G12C and ASO-G12C-LNA, 2) G12D using ASO16-G12D and ASO16-G12D-LNA, 3) G12V using ASO16-G12V and ASO16-G12V-LNA and 4) G13D using ASO16-G13D and ASO16-G13D-LNA. These results indicate that the increased mutation specificity of these ASO sequences led to increased potency.

[0235] The effect of LNAs on ASO16 activity was tested. A MIAPaCa-2 pancreatic cancer cell line expressing a KRAS G12C mutation was tested by free ASO uptake. The cell line was treated with ASO16, ASO16 C12C, or ASO16 G12C with 1, 2, or 3 LNAs surrounding the site of mis-match at 1 μ M or 5 μ M for 72 hours, and qPCR was run. The results are shown in **FIG. 10**. The results show significant improvements in KRAS silencing with increasing LNAs at the mis-match sites.

[0236] The ability to spare wild-type KRAS expression was tested with the same ASOs. A luciferase reporter system was used in A431 cells in which the endogenous KRAS wild-type allele was deleted to avoid competition for the ASOs. These A431-KRAS null lines were

then engineered to express either wild-type KRAS or KRAS G12C tagged with a firefly luciferase reporter. Upon exposure to 5 μ M of ASOs by free uptake for 72 hours, the ASOs showed significant wild-type sparing compared with G12C silencing, most notably in the ASO16-G12C ASOs with LNA modifications (**FIG. 11**).

EXAMPLE 4

Fully Modified siRNA Sequences

[0237] Several of the ASOs targeted to single KRAS mutations described in Example 3 were converted to siRNA molecules in an effort to identify sequences that maximize the reduction of expression of mutated sequences while sparing the wild-type KRAS sequence. These siRNAs were then fully modified (FM) to minimize nuclease degradation and immune stimulation. While these types of modifications often attenuate the silencing activity of siRNAs, the inventors have developed several fully modified siRNA sequences that retain all or nearly all of their silencing activity compared to unmodified siRNAs.

[0238] **Table 4** lists the fully modified siRNA sequences that were prepared.

[0239] Each of the siRNAs was tested in A431 cells engineered to either express WT or the targeted KRAS mutation. For mutant expressing A431 cells, the WT allele was deleted via CRISPR, so the expression shown is only reflective of the mutant mRNA. Cells were transfected with a low dose (20 nM) of negative control (NC) or the FM KRAS siRNAs and qPCR for KRAS expression was run on RNA isolated 24 hours later.

Table 4: Fully modified siRNA sequences

Name	Strand	Sequence (5'-3')	SEQ ID NO
D1-G12C-FM	S	[mG]*[mA]*[mG][mC][mU][mU][2fHG][mU][2fHG][2fHG][2fHG][mG][mU][mA][mG][mC][mA][mA][mG][mG][mA]	78
(D1-G12C-DV22)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mC][mC][mA][mC][2fA][mA][2fHG][mC][mU][mC]*[mC]*[mA]	79
D1-G12D-FM	S	[mG]*[mA]*[mG][mC][mU][mG][2fA][mU][2fHG][2fHG][2fHG][mG][mU][mA][mG][mC][mA][mA][mG][mG][mA]	80
(D1-G12D-DV22)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mC][mC][mA][mU][2fC][mA][2fHG][mC][mU][mC]*[mC]*[mA]	81
D1-G13D-FM	S	[mG]*[mA]*[mG][mC][mU][mG][2fHG][mU][2fHG][2fA][2fHG][mG][mU][mA][mG][mC][mA][mA][mG][mG][mA]	82
(D1-G13D-DV22)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mU][mC][mA][mC][2fC][mA][2fHG][mC][mU][mC]*[mC]*[mA]	83
D2-G12C-FM	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG][mG]	84
(D2-G12C-DV22)	AS	[mU]*[2fA]*[mC][mG][mC][2fC][mA][mG][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	85
D2-G12D-FM	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG][mG]	86
(D2-G12D-DV22)	AS	[mU]*[2fA]*[mC][mG][mC][2fC][mA][mG][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	87
D2-G13D-FM	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG][mG]	88
(D2-G13D-DV22)	AS	[mU]*[2fA]*[mC][mG][mC][2fC][mA][mG][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	89
D4-G13D-FM	S	[mG]*[mG]*[mU][mA][mG][mU][2fU][mG][2fHG][2fHG][2fHG][mG][mU][mG][mC][mG][mA][mC][mG][mU]	90
(D4-G13D-DV22)	AS	[mG]*[2fU]*[mC][mA][mC][2fC][mA][mG][mC][mU][mC][mC][mU][mG][mC][mU][mG][mC][mC]*[mA]*[mC]	91
D1-G12V-FM	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG][mG]	92
(D1-G12V-DV22)	AS	[mU]*[2fA]*[mC][mG][mC][2fC][mA][mG][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	93
D2-G12V-FM	S	[mG]*[mA]*[mG][mC][mU][mG][2fHG][mU][2fHG][2fHG][2fHG][mG][mU][mA][mG][mC][mA][mA][mG][mG][mA]	94
(D2-G12V-DV22)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mC][mC][mA][mA][2fC][mA][2fHG][mC][mU][mC]*[mC]*[mA]	95
D1-G12D-FM-F	S	[mG]*[mA]*[mG][mC][mU][mG][2fA][mU][2fHG][2fHG][2fHG][mG][mU][mA][mG][mC][mA][mA][mG][mG][mA]	96
(D1-G12D-DV22-F)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mC][mC][mA][2fU][2fC][mA][2fHG][mC][mU][mC]*[mC]*[mA]	97
D1-G13D-FM-F	S	[mG]*[mA]*[mG][mC][mU][mG][2fHG][mU][2fHG][2fA][2fHG][mG][mU][mA][mG][mC][mA][mA][mG][mG][mA]	98
(D1-G13D-DV22-F)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mU][mC][mA][mC][2fC][mA][2fHG][mC][mU][mC]*[mC]*[mA]	99

D2-G12C-DM-F	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG][mG]	100
(D2-G12C-DV22-F)	AS	[mU]*[2fA]*[mC][mC][mG][2fC][mA][mC][2fA][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	101
D2-G12D-FM-F	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG]	102
(D2-G12D-DV22-F)	AS	[mU]*[2fA]*[mC][mC][mG][2fC][mA][mC][2fA][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	103
D2-G13D-FM-F	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG]	104
(D2-G13D-DV22-F)	AS	[mU]*[2fA]*[mC][mC][mG][2fC][mA][mC][2fA][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	105
D1-G12V-FM-F	S	[mA]*[mG]*[mU][mU][mG][mG][2fA][mG][2fC][2fU][2fU][mG][mU][mG][mC][mG][mU][mA][mG][mG]	106
(D1-G12V-DV22-F)	AS	[mU]*[2fA]*[mC][mC][mG][2fC][mA][mC][2fA][mC][mU][2fC][mC][2fA][mA][mC][mU]*[mA]*[mC]	107
D2-G12V-FM-F	S	[mG]*[mA]*[mG][mC][mU][mG][2fU][mU][2fG][2fC][mG][mU][mA][mG][mC][mC][mA][mG][mG][mA]	108
(D2-G12V-DV22-F)	AS	[mU]*[2fU]*[mG][mC][mC][2fU][mA][mC][mG][mC][mC][2fA][2fC][mA][2fG][mC][mA][mC]*[mA]	109
Seq2-FM	S	[mG]*[mU]*[mC][mU][mC][mU][2fU][mG][2fG][2fA][mU][mU][mC][mU][mC][mG][mA]	110
(Seq2-DV22)	AS	[mU]*[2fC]*[mG][mA][mG][2fA][mA][mU][mC][mC][mC][2fA][mG][2fA][mC][mC]*[mA]*[mG]	111
Seq3-FM	S	[mC]*[mA]*[mG][mC][mU][mA][2fA][mU][2fU][2fC][2fA][mG][mA][mU][mC][mA][mU]	112
(Seq3-DV22)	AS	[mA]*[2fA]*[mU][mG][mA][2fU][mU][mC][mU][mG][mA][mU][2fU][mA][2fG][mC][mU][mG]*[mU]*[mA]	113
D1-G12C-Hi2F	S	[2fU]*[mG]*[2fG][mA][2fG][mC][2fU][mU][2fG][2fU][mG][2fC][mG][2fU][mA][2fG][mG][2fC][mA][2fA]	162
	AS	[mU]*[2fU]*[mG][2fC][mC][2fU][mA][2fC][mC][mC][2fA][mC][2fA][mC][2fU][mC][2fC][mA]*[mC]	163
D1-G12D-Hi2F	S	[2fU]*[mG]*[2fG][mA][2fG][mC][2fU][mU][2fG][2fU][mG][2fC][mG][2fU][mA][2fG][mG][2fC][mA][2fA]	164
	AS	[mU]*[2fU]*[mG][2fC][mC][2fU][mA][2fC][mC][mC][2fA][mC][2fA][mC][2fU][mC][2fC][mA]*[mC]	165
D1-G13D-Hi2F	S	[2fU]*[mG]*[2fG][mA][2fG][mC][2fU][mU][2fG][2fU][mG][2fC][mG][2fU][mA][2fG][mG][2fC][mA][2fA]	166
(EFTX-G13D-FM1)	AS	[mU]*[2fU]*[mG][2fC][mC][2fU][mA][2fC][mC][mC][2fA][mC][2fA][mC][2fU][mC][2fC][mA]*[mC]	167
V2-G12V-Hi2F	S	[2fU]*[mG]*[2fG][mA][2fG][mC][2fU][mU][2fG][2fU][mG][2fC][mG][2fU][mA][2fG][mG][2fC][mA][2fA]	168
(EFTX-3G12V2)	AS	[mU]*[2fU]*[mG][2fC][mC][2fU][mA][2fC][mC][mC][2fA][mC][2fA][mC][2fU][mC][2fC][mA]*[mC]	169
D2-G12C-Hi2F	S	[2fG]*[mU]*[2fA][mG][2fU][mU][2fG][2fA][2fG][mG][2fU][mG][2fU][mC][2fG][mU][2fA]	170
	AS	[mU]*[2fA]*[mC][2fG][mC][2fC][mA][2fC][mA][mG][mC][mU][2fC][mC][2fA][mA][2fC][mU][2fA][mC]*[mA]	171
D2-G12D-Hi2F	S	[2fG]*[mU]*[2fA][mG][2fU][mU][2fG][2fA][2fG][mG][2fU][mG][2fU][mC][2fG][mU][2fA]	172

	AS	[mU]*[2PA]*[mU]*[2PA]*[mc][2fG][mc][2fG][mC][2fU][mU][2fC][mC][2fA][mG][mC][mU][2fC][mC][2fA][mC]*[mC]*[mA]	173
D2-G13D-HI2F (EFTX-G13D-FM2)	S	[2fG]*[mU]*[2PA][mG][2fU][mU][2fG][mG][2fA][2fG][2fC][mU][2fG][mG][2fU][mG][2fA][mC][2fG][mU][2fA]	174
	AS	[mU]*[2PA]*[mC][2fG][mU][2fC][mC][2fA][2fC][mC][2fA][mG][mC][mU][2fC][mC][2fA][mC]*[mC]*[mA]	175
V1-G12V-HI2F (EFTX-3G12V1)	S	[2fG]*[mU]*[2PA][mG][2fU][mU][2fG][mG][2fA][2fG][2fC][mU][2fG][mG][2fU][mG][2fG][mU][2fA]	176
	AS	[mU]*[2PA]*[mC][2fG][mC][2fC][mC][2fA][mG][mC][mU][2fC][mC][2fA][mC][2fA][mC]*[mC]*[mA]	177
D4-G12C-HI2F	S	[2fG]*[mU]*[2fG][mG][2fU][mC][2fG][mU][2fG][mC][2fU][mU][2fG][mU][2fG][mG][2fC]	178
	AS	[mG]*[2fC]*[mC][2fA][mC][2fU][mC][mC][mC][2fA][mC][2fU][mC][2fA][mC][2fA][mC]*[mA]*[mA]	179
D4-G13D-HI2F	S	[2fG]*[mU]*[2fG][mG][2fU][mC][2fG][mU][2fG][mC][2fU][mC][2fA][mG][2fG][mC][2fU][mG][2fG][mG][2fC]	180
	AS	[mG]*[2fC]*[mC][2fA][mU][2fC][mC][2fG][mC][2fU][mC][2fA][mC][2fC][mC][2fA][mC]*[mA]*[mA]	181
D4-G13D-HI2F (EFTX-G13D-FM4)	S	[2fG]*[mU]*[2fG][mG][2fU][mC][2fG][mU][2fG][mC][2fU][mC][2fG][mC][2fU][mG][2fG][mU][2fG][mC][2fC]	182
	AS	[mG]*[2fU]*[mC][2fA][mC][2fC][mC][2fG][mC][2fU][mC][2fA][mC][2fC][mC][2fA][mC]*[mA]*[mA]	183
V4-G12V-HI2F (EFTX-3G12V4)	S	[2fG]*[mU]*[2fG][mG][2fU][mC][2fG][mU][2fG][mC][2fU][mC][2fG][mC][2fU][mG][2fG][mU][2fG][mC][2fC]	184
	AS	[mG]*[2fC]*[mC][2fA][mC][2fU][mC][mC][mC][2fA][mC][2fU][mC][2fC][mC][2fA][mC]*[mA]*[mA]	185

S – sense strand

AS – antisense strand

m - 2'-O-methyl on sugar moieties

2f - 2'-fluoro on sugar moieties

* - phosphorothioate in between nucleotides

[0240] For siRNAs targeting the G12C mutation, it was found that D1-G12C-FM and D2-G12C-FM were both able to reduce mutant KRAS G12C while sparing the wild-type expression (**FIG. 12**). Notably, not all of the siRNAs were equivalent in suppressing G12C KRAS or sparing wild-type KRAS. As shown in **FIG. 13**, it was found that some (hatched bars) mutant-specific (MS) iterations of the ‘parent’ D1 (12CD13D_1), D2 (12CD13D_2), and D4 (12CD13D_4) sequences were more potent (panel 1). It was found that several of the MS sequences more potently reduced the mutant over WT sequences (see D1-G12C, D2-G12C, D4-G12C), unlike a pan-KRAS Seq 2 (panel 2). Finally, it was found that FM iterations of these MS sequences showed retained silencing activity on mutant KRAS over WT KRAS expression (*e.g.*, D2-G12C-FM-F) (panel 3).

[0241] For siRNAs targeting the G12D mutation, it was found that D1-G12D-FM, D2-G12D-FM and D2-G12D-FM-F were all able to reduce mutant KRAS G12D (**FIG. 14**). D1-G12D-FM and D2-G12D-FM were also able to spare WT expression (**FIG. 14**). Notably, not all of the siRNAs were equivalent in suppressing G12D KRAS or sparing wild-type KRAS. As shown in **FIG. 15**, it was found that some (hatched bars) mutant-specific (MS) iterations of the ‘parent’ D1, D2 and D4 sequences were more potent (panel 1). It was found that several of the MS sequences more potently reduced the mutant over WT sequences (see D1-G12D), unlike a pan-KRAS Seq 2 (panel 2). Finally, it was found that FM iterations of these MS sequences showed retained silencing activity on mutant KRAS over WT KRAS expression (*e.g.*, D1-G12D-FM and D2-G12D-FM) (panel 3).

[0242] For siRNAs targeting the G12V mutation, it was found that V1-G12V-FM and V2-G12V-FM were able to reduce mutant KRAS G12V while also able to spare WT expression (**FIG. 16**). Notably, not all of the siRNAs were equivalent in suppressing G12V KRAS or sparing wild-type KRAS. As shown in **FIG. 17**, it was found that some (hatched bars) mutant-specific (MS) iterations of the ‘parent’ D1, D2 and D4 sequences were more potent (panel 1). It was found that several of the MS sequences more potently reduced the mutant over WT sequences (see D2-G12V), unlike a pan-KRAS Seq 2 (panel 2). Finally, it was found that FM iterations of these MS sequences showed retained silencing activity on mutant KRAS over WT KRAS expression (*e.g.*, D1-G12V-FM and D2-G12V-FM) (panel 3).

[0243] For siRNAs targeting the G13D mutation, it was found that D2-G13D-FM and D2-G13D-FM-F were able to reduce mutant KRAS G13D (**FIG. 18**). D2-G13D-FM-F was also able to spare WT expression (**FIG. 18**). Notably, not all of the siRNAs were equivalent in suppressing G13D KRAS or sparing wild-type KRAS. As shown in **FIG. 19**, it was found that some (hatched bars) mutant-specific (MS) iterations of the ‘parent’ D1, D2 and D4

sequences were more potent (panel 1). It was found that several of the MS sequences more potently reduced the mutant over WT sequences (see D1-G13D and D4-G13D), unlike a pan-KRAS Seq 2 (panel 2). Finally, it was found that FM iterations of these MS sequences showed retained silencing activity on mutant KRAS over WT KRAS expression (*e.g.*, D2-G13D-FM and D2-G13D-FM-F) (panel 3).

[0244] G12D-targeted siRNAs were tested for effects on cell viability using A427 (KRAS G12D) lung cancer cells. Cells were transfected with the siRNAs and cell viability measured after either 5 (D5) or 8 (D8) days using CELLTITER_GLO[®] luminescent read-out. The results reveal the D2-G12D Hi2F and D4-G12D Hi2F siRNAs are highly potent against the G12D lines as shown in **FIG. 20**.

[0245] Similar experiments were run to determine IC₅₀ (*i.e.*, GI 50) values for the siRNAs. Results are shown in **Table 5** and **FIG. 21**.

Table 5

GI 50	Expt 1	Expt 2
	10,000 cells 5.5 days 40 nM	8,000 cells 4.5 days 20 nM
Msnord90	18.43	12.39
mTTR Hi2F	14.16	19.06
Seq3 unmod	0.9768	1.906
D1 unmod	8.583	183.2
D1-G12D unmod	3.469	2.987
D1-G12D Hi2F	28.96	20.84
D2 unmod	Undefined	18.31
D2-G12D unmod	1.144	2.009
D2-G12D Hi2F	16.58	12.13
D4 unmod	20.72	19.78
D4-G12D unmod	16.57	14.16
D4-G12D Hi2F	20.98	17.5

[0246] Similar cell viability studies were performed with G13D-targeted siRNAs in HCT116 (KRAS G13D) colon cancer cells. Results reveal that all of the D2-G13D fully modified siRNAs are highly potent to inhibit cancer cell viability as shown in **FIG. 22**.

[0247] Similar experiments were run to determine IC₅₀ values for the siRNAs. Results are shown in **FIG. 23**. Additionally, qPCR experiments were performed in the A431 WT and KRAS G13D models to show up to 5-fold sparing of wild-type KRAS with EFTX-G13D-F2, the most potent siRNA (**FIG. 23**).

[0248] To study in vivo efficacy, HCT116 (KRAS G13D) tumors were established as xenografts in athymic nude mice until they reached about 125 mm³ in size, and then treated with either PBS or an EGFR-targeting ligand (GE11) conjugated to D2-G13D-Hi2F siRNA with the shown linkers (**FIG. 24**). The mice were treated subcutaneously with the GE11-siRNAs (5 mg/kg) suspended in sterile PBS. The results showed up to 50-70% silencing of KRAS in the tumors at the indicated timepoints (**FIG. 24**). Each group and timepoint indicated represents 5 independent tumors.

[0249] G12V-targeted siRNAs were tested for effects on cell viability using SKC01 (KRAS G12V) colon cancer cells. Cells were transfected with the siRNAs and cell viability measured after either 5 (D5) or 8 (D8) days using CELLTITER_GLO[®] luminescent read-out. The results reveal substantial anti-cancer activity with both the V1-G12V and V4-G12V fully modified siRNAs as shown in **FIG. 25**.

[0250] Similar experiments were run to determine IC₅₀ values for the siRNAs. Results are shown in **FIG. 26**. Additionally, qPCR experiments were performed in the A431 WT and KRAS G12V models to show sparing of wild-type KRAS with EFTX-3G12V1 and EFTX-3G12V4 (**FIG. 26**).

[0251] The effect of EFTX-D1 on KRAS expression was tested in NIH/3T3 cells. **FIG. 27A** shows a Western blot of NIH/3T3 cells stably expressing HA-tagged KRAS WT or G12C 36 hours post transient transfection with NC siRNA, Seq2 siRNA, or EFTX-D1 siRNA at 20 nM. Cell lysate was blotted for HA (KRAS) and β -actin (loading control). Densitometry is shown to the right, and results are normalized to NC siRNA transfection and β -actin expression. **FIG. 27B** shows a Western blot of A431 cells stably expressing HA-tagged KRAS WT, G12C, or G12D 48 hours post transient transfection with NC siRNA, Seq2 siRNA, or EFTX-D1 siRNA at 20 nM. Cell lysate was blotted for HA (KRAS) and vinculin (loading control). Densitometry is shown to the right, and results are normalized to NC siRNA transfection and vinculin expression and reveal on a protein level that EFTX-D1 can more potently silence mutant KRAS expression and spare the wild-type levels.

EXAMPLE 5**Additional Fully Modified siRNA Sequences**

[0252] siRNAs comprising the sequence of SEQ ID NO:50 or SEQ ID NO:51 were used as positive controls in the experiments described in Example 1. Fully modified versions of these siRNAs were prepared to test their specificity and potency. The sequences of the FM siRNAs are shown in **Table 4**. The HCT116 (colon cancer, KRAS G13D) and LU65 (lung cancer, KRAS G12C) cell lines were transfected with 20 nM of either unmodified Seq2 or Seq3, or fully chemically modified (FM) Seq2-FM or Seq3-FM siRNA sequences. Both Seq2-FM and Seq3-FM surprisingly maintained full silencing of KRAS activity, especially at 48 hours post-treatment (**FIG. 28**).

[0253] All publications, patents, and patent applications are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0254] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the list of the foregoing embodiments and the appended claims.

WHAT IS CLAIMED IS:

1. An antisense oligonucleotide targeted to a synthetic human KRAS mRNA that encodes the missense mutations G12C, G12D, and G13D, wherein the antisense oligonucleotide is 16-25 nucleotides in length and comprises the sequence TCTTGCCTACGTCATA (SEQ ID NO:114).
2. The antisense oligonucleotide of claim 1, wherein the antisense oligonucleotide is 20 nucleotides in length.
3. The antisense oligonucleotide of claim 1 or 2, consisting of the sequence CACTCTTGCCTACGTCATAA (SEQ ID NO:115).
4. The antisense oligonucleotide of claim 1 or 2, consisting of the sequence GCACTCTTGCCTACGTCATA (SEQ ID NO:116).
5. The antisense oligonucleotide of any one of claims 1-4, wherein the antisense oligonucleotide comprises at least one phosphorothioate linkage.
6. The antisense oligonucleotide of claim 5, wherein the antisense oligonucleotide comprises all phosphorothioate linkages.
7. The antisense oligonucleotide of any one of claims 1-6, wherein the antisense oligonucleotide comprises at least one modified nucleotide at or near the 5' end and/or the 3' end.
8. The antisense oligonucleotide of claim 7, wherein the antisense oligonucleotide comprises at least three modified nucleotides at each of the 5' end and the 3' end.
9. The antisense oligonucleotide of claim 7 or 8, wherein the modified nucleotide is a 2'-O-methoxyethyl (2'-MOE)-modified nucleotide.

10. The antisense oligonucleotide of claim 9, wherein the antisense oligonucleotide comprises at least three 2'—MOE-modified nucleotides at each of the 5' end and/or the 3' end.

11. The antisense oligonucleotide of claim 10, wherein the antisense oligonucleotide consists of a sequence selected from:

a) **C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A*A** (SEQ ID NO:68);

or

b) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*T*A** (SEQ ID NO:69);

wherein * indicates a phosphorothioate linkage and bold indicates a 2'—MOE-modified nucleotide.

12. The antisense oligonucleotide of any one or claims 7-9, wherein at least one modified nucleotide is a locked nucleic acid.

13. An antisense oligonucleotide targeted to a naturally-occurring human KRAS mRNA encoding a mutation selected from G12C, G12D, G12V, and G13D, wherein the antisense oligonucleotide is 16-25 nucleotides in length and comprises a sequence selected from:

a) TCTTGCCTACGCCACA (SEQ ID NO:117) targeted to a human KRAS mRNA encoding a G12C mutation;

b) TCTTGCCTACGCCATC (SEQ ID NO:118) targeted to a human KRAS mRNA encoding a G12D mutation;

c) TCTTGCCTACGCCAAC (SEQ ID NO:119) targeted to a human KRAS mRNA encoding a G12V mutation;

d) TCTTGCCTACGTCACC (SEQ ID NO:120) targeted to a human KRAS mRNA encoding a G13D mutation; or

e) a sequence at least 90% identical to any one of a) to d);

wherein the antisense oligonucleotide comprises at least one non-naturally occurring chemical modification.

14. The antisense oligonucleotide of claim 13, wherein the antisense oligonucleotide is 20 nucleotides in length.

15. The antisense oligonucleotide of claim 13 or 14, wherein the antisense oligonucleotide consists of a sequence selected from:
- a) GCACTCTTGCCTACGCCACA (SEQ ID NO:117) targeted to a human KRAS mRNA encoding a G12C mutation;
 - b) GCACTCTTGCCTACGCCATC (SEQ ID NO:118) targeted to a human KRAS mRNA encoding a G12D mutation;
 - c) GCACTCTTGCCTACGCCAAC (SEQ ID NO:119) targeted to a human KRAS mRNA encoding a G12V mutation; or
 - d) GCACTCTTGCCTACGTCACC (SEQ ID NO:120) targeted to a human KRAS mRNA encoding a G13D mutation.
16. The antisense oligonucleotide of any one of claims 13-15, wherein the antisense oligonucleotide comprises at least one phosphorothioate linkage.
17. The antisense oligonucleotide of claim 16, wherein the antisense oligonucleotide comprises all phosphorothioate linkages.
18. The antisense oligonucleotide of any one of claims 13-17, wherein the antisense oligonucleotide comprises at least one modified nucleotide at or near the 5' end and/or the 3' end.
19. The antisense oligonucleotide of claim 18, wherein the antisense oligonucleotide comprises at least three modified nucleotides at each of the 5' end and the 3' end.
20. The antisense oligonucleotide of claim 18 or 19, wherein the modified nucleotide is a 2'—MOE-modified nucleotide.
21. The antisense oligonucleotide of claim 20, wherein the antisense oligonucleotide comprises at least three 2'—MOE-modified nucleotides at each of the 5' end and/or the 3' end.
22. The antisense oligonucleotide of claim 21, wherein the antisense oligonucleotide consists of a sequence selected from:
- a) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C*A** (SEQ ID NO:70);

- b) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*T*C** (SEQ ID NO:71);
- c) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*A*C** (SEQ ID NO:72);

or

- d) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*T*C*A*C*C** (SEQ ID NO:73);

wherein * indicates a phosphorothioate linkage and bold indicates a 2'—MOE-modified nucleotide.

23. The antisense oligonucleotide of any one of claims 18-20, wherein at least one modified nucleotide is a locked nucleic acid.

24. The antisense oligonucleotide of claim 23, wherein the antisense oligonucleotide consists of a sequence selected from:

- a) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A*C**+A (SEQ ID NO:74);
- b) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A**+T*C (SEQ ID NO:75);
- c) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A**+A*C (SEQ ID NO:76);
- d) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G**+T*C*A*C*C (SEQ ID NO:77);
- e) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C*C*A**+C+A (SEQ ID

NO:160); or

- f) **G*C*A*C*T*C*T*T*G*C*C*T*A*C*G*C**+A+C+A (SEQ ID

NO:161);

wherein * indicates a phosphorothioate linkage, bold indicates a 2'—methoxymethyl-modified nucleotide, and + indicates the following nucleotide is a locked nucleic acid.

25. A nucleic acid construct comprising the antisense oligonucleotide of any one of claims 1-4 or 13-15.

26. A nucleic acid molecule encoding the antisense oligonucleotide of any one of claims 1-4 or 13-15.

27. A nucleic acid construct comprising the nucleic acid molecule of claim 26.

28. A siRNA molecule targeted to a naturally-occurring human KRAS mRNA encoding a mutation selected from G12C, G12D, G12V, or G13D, wherein the siRNA molecule

comprises at least one chemical modification, and wherein the siRNA molecule comprises one of the following pairs of sequences:

sense strand of SEQ ID NO:128 and antisense strand of SEQ ID NO: 129;
sense strand of SEQ ID NO:130 and antisense strand of SEQ ID NO: 131;
sense strand of SEQ ID NO:132 and antisense strand of SEQ ID NO: 133;
sense strand of SEQ ID NO:134 and antisense strand of SEQ ID NO: 135;
sense strand of SEQ ID NO:136 and antisense strand of SEQ ID NO: 137;
sense strand of SEQ ID NO:138 and antisense strand of SEQ ID NO: 139;
sense strand of SEQ ID NO:140 and antisense strand of SEQ ID NO: 141;
sense strand of SEQ ID NO:142 and antisense strand of SEQ ID NO: 143;
sense strand of SEQ ID NO:144 and antisense strand of SEQ ID NO: 145;
sense strand of SEQ ID NO:146 and antisense strand of SEQ ID NO: 147;
sense strand of SEQ ID NO:148 and antisense strand of SEQ ID NO: 149;
sense strand of SEQ ID NO:150 and antisense strand of SEQ ID NO: 151;
sense strand of SEQ ID NO:152 and antisense strand of SEQ ID NO: 153;
sense strand of SEQ ID NO:154 and antisense strand of SEQ ID NO: 155;
sense strand of SEQ ID NO:156 and antisense strand of SEQ ID NO: 157; or
sense strand of SEQ ID NO:158 and antisense strand of SEQ ID NO: 159;

or a sequence at least 90% identical thereto.

29. The siRNA molecule of claim 28, which is fully chemically-modified.
30. The siRNA molecule of claim 29, wherein each nucleotide in the siRNA molecule is modified with a 2'-O-methyl group or a 2'-fluoro group.
31. The siRNA molecule of any one of claims 28-30, wherein the siRNA molecule comprises at least one phosphorothioate linkage.
32. The siRNA molecule of any one of claims 28-31, comprising a sense strand and an antisense strand, wherein the siRNA molecule comprises one of the following pairs of sequences:
- sense strand of SEQ ID NO:78 and antisense strand of SEQ ID NO:79;
sense strand of SEQ ID NO:80 and antisense strand of SEQ ID NO:81;
sense strand of SEQ ID NO:82 and antisense strand of SEQ ID NO:83;

sense strand of SEQ ID NO:84 and antisense strand of SEQ ID NO:85;
sense strand of SEQ ID NO:86 and antisense strand of SEQ ID NO:87;
sense strand of SEQ ID NO:88 and antisense strand of SEQ ID NO:89;
sense strand of SEQ ID NO:90 and antisense strand of SEQ ID NO:91;
sense strand of SEQ ID NO:92 and antisense strand of SEQ ID NO:93;
sense strand of SEQ ID NO:94 and antisense strand of SEQ ID NO:95;
sense strand of SEQ ID NO:96 and antisense strand of SEQ ID NO:97;
sense strand of SEQ ID NO:98 and antisense strand of SEQ ID NO:99;
sense strand of SEQ ID NO:100 and antisense strand of SEQ ID NO:101;
sense strand of SEQ ID NO:102 and antisense strand of SEQ ID NO:103;
sense strand of SEQ ID NO:104 and antisense strand of SEQ ID NO:105;
sense strand of SEQ ID NO:106 and antisense strand of SEQ ID NO:107;
sense strand of SEQ ID NO:108 and antisense strand of SEQ ID NO:109;
sense strand of SEQ ID NO:162 and antisense strand of SEQ ID NO:163;
sense strand of SEQ ID NO:164 and antisense strand of SEQ ID NO:165;
sense strand of SEQ ID NO:166 and antisense strand of SEQ ID NO:167;
sense strand of SEQ ID NO:168 and antisense strand of SEQ ID NO:169;
sense strand of SEQ ID NO:170 and antisense strand of SEQ ID NO:171;
sense strand of SEQ ID NO:172 and antisense strand of SEQ ID NO:173;
sense strand of SEQ ID NO:174 and antisense strand of SEQ ID NO:175;
sense strand of SEQ ID NO:176 and antisense strand of SEQ ID NO:177;
sense strand of SEQ ID NO:178 and antisense strand of SEQ ID NO:179;
sense strand of SEQ ID NO:180 and antisense strand of SEQ ID NO:181;
sense strand of SEQ ID NO:182 and antisense strand of SEQ ID NO:183; or
sense strand of SEQ ID NO:184 and antisense strand of SEQ ID NO:185.

33. An siRNA molecule targeted to human KRAS mRNA, wherein the sense strand of the siRNA comprises the sequence of SEQ ID NO:50 or SEQ ID NO:51, and wherein the siRNA comprises at least one non-naturally occurring chemical modification.
34. The siRNA molecule of claim 33, wherein the siRNA is chemically-modified.
35. The siRNA molecule of claim 34, wherein the siRNA is fully chemically-modified.

36. The siRNA molecule of claim 35, wherein each nucleotide in the siRNA molecule is modified with a 2'-O-methyl group or a 2'-fluoro group.
37. The siRNA molecule of any one of claims 33-36, wherein the siRNA molecule comprises at least one phosphorothioate linkage.
38. The siRNA molecule of any one of claims 33-37, comprising a sense strand and an antisense strand, wherein the siRNA molecule comprises one of the following pairs of sequences:
sense strand of SEQ ID NO:110 and antisense strand of SEQ ID NO:111; or
sense strand of SEQ ID NO:112 and antisense strand of SEQ ID NO:113.
39. A composition comprising the antisense oligonucleotide of any one of claims 1-24 or the siRNA of any one of claims 28-38.
40. A composition comprising two or more of the antisense oligonucleotide of any one of claims 1-24 or the siRNA of any one of claims 28-38 in any combination, wherein the two or more antisense oligonucleotides or siRNAs each comprise a different sequence.
41. The composition of claim 39 or 40, further comprising a nanoparticle.
42. The composition of claim 41, wherein the nanoparticle is a nanoliposome.
43. A pharmaceutical composition comprising the antisense oligonucleotide of any one of claims 1-24, the nucleic acid construct of any one of claims 25 or 27, the siRNA of any one of claims 28-38, and/or the composition of any one of claims 39-42 and a pharmaceutically acceptable carrier.
44. A method of inhibiting expression of a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D in a cell, the method comprising contacting the cell with the antisense oligonucleotide of any one of claims 1-24, the nucleic acid construct of any one of claims 25 or 27, the siRNA of any one of claims 28-38, the composition of any one of claims 39-42, and/or the pharmaceutical composition of claim 43, thereby inhibiting expression of the mutant human KRAS gene in the cell.

45. A method of treating cancer in a subject in need thereof, wherein the cancer comprises a mutant human KRAS gene comprising one or more of the missense mutations G12C, G12D, G12V, and G13D, the method comprising delivering to the subject the antisense oligonucleotide of any one of claims 1-24, the nucleic acid construct of any one of claims 25 or 27, the siRNA of any one of claims 28-38, the composition of any one of claims 39-42, and/or the pharmaceutical composition of claim 43, thereby treating cancer in the subject.

46. The method of claim 45, wherein the delivery is systemic delivery.

	CODON		SEQ ID NO:
	12	13	
<u>KRAS GENE:</u>			
<u>WILD-TYPE</u>	ACTGAATATAAACTTGTGGTAGTTGGAGCTGGT	GGC	40
<u>G12C MUT</u>	ACTGAATATAAACTTGTGGTAGTTGGAGCTTGT	GGC	41
<u>G12D MUT</u>	ACTGAATATAAACTTGTGGTAGTTGGAGCTGAT	GGC	42
<u>G12V MUT</u>	ACTGAATATAAACTTGTGGTAGTTGGAGCTGTT	GGC	43
<u>G13D MUT</u>	ACTGAATATAAACTTGTGGTAGTTGGAGCTGGT	GAC	44
<u>siRNA:</u>			
<u>G12C</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GGC	45
<u>G12D</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GGC	46
<u>12CD13D_1</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GAC	47
<u>12CD13D_2</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GAC	47
<u>12CD13D_3</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GAC	47
<u>12CD13D_4</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GAC	47
<u>12CV13D_1</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GAC	48
<u>12CV13D_2</u>	ACUGAAUAUAAAACUUUGGUA <u>GUUGGAGCUU</u> GUU	GAC	48
<u>CONTROL siRNA:</u>			
<u>NC</u>	<u>UUCUCCGAA</u> CGUGUCACGU		49
<u>SEQ2</u>	<u>GUCUCUUGGAU</u> AUUCUCGA		50
<u>SEQ3</u>	<u>CAGCUAAUU</u> CAGAAUCAUU		51

FIG. 1




FIG. 2A




FIG. 2B

4/25




FIG. 3

CUSTOM siRNA (TESTED):	CODON		SEQ ID NO:
	12	13	
G12C	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UGUGGC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	45
G12D	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>GAU</u> GGC <u>GUA</u> GGCAAAGAGUGCCUUGACGAUACAG	46
12CD13D_1	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_2	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_3	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_4	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CV13D_1	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UUU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	48
12CV13D_2	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UUU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	48
<u>SEQUENCES IN BETWEEN CUSTOM siRNAs:</u>			
12CD13D_A	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_B	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_C	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_D	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_E	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
12CD13D_F	ACUGAAUAUAAAACUUUGGGUAUUUGGAGCUU	<u>UAU</u> G <u>AC</u> GUA <u>GGCAA</u> GAGUGCCUUGACGAUACAG	47
<u>CONTROL siRNA:</u>			
NC	UUUCUCCGAAACGUGUCACGU		49
SEQ2	<u>GUCUCUUGGAUAUUCUCGA</u>		50
SEQ3	<u>CAGCUAAUUCAGAAUCAUU</u>		51

FIG. 4




FIG. 5




FIG. 7




FIG. 8

10/25




FIG. 9

11/25




FIG. 10

12/25




FIG. 11

13/25




FIG. 12




FIG. 13

14/25




FIG. 14




FIG. 15




FIG. 16




FIG. 17

16/25




FIG. 18




FIG. 19

17/25




FIG. 20

18/25




FIG. 21

19/25




FIG. 22

20/25




FIG. 23

21/25




FIG. 24

22/25




FIG. 25




FIG. 26




FIG. 27





FIG. 28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2021/026147

A. CLASSIFICATION OF SUBJECT MATTER C12N 15/113(2010.01)i; A61P 35/00(2006.01)i		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C12N 15/113(2010.01); A61K 31/713(2006.01); A61K 45/06(2006.01); A61K 9/107(2006.01); C07H 21/02(2006.01); G01N 33/50(2006.01)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Korean utility models and applications for utility models Japanese utility models and applications for utility models		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) eKOMPASS(KIPO internal) & Keywords: KRAS, G12C, G12D, G12V, G13D, mutation, target, inhibit, oligonucleotide, siRNA, interfering, modification		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	US 2010-0286241 A1 (XIE, F. Y. et al.) 11 November 2010 (2010-11-11) abstract, claims 1-2, paragraphs [0072], [0074]-[0075], [0079], [0147], tables 3-4, SEQ ID NOs : 63-64, 119-120	28-31 1-4,13-15,33-37
X A	US 2015-0238515 A1 (ARROWHEAD RESEARCH CORPORATION) 27 August 2015 (2015-08-27) abstract, claim 1, paragraphs [0046]-[0047], [0049], [0075], [0263], table 3, SEQ ID NOs : 1067, 1121	33-37 1-4,13-15,28-31
A	US 2019-0055562 A1 (THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL) 21 February 2019 (2019-02-21) the whole document	1-4,13-15,28-31,33-37
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>“A” document defining the general state of the art which is not considered to be of particular relevance</p> <p>“D” document cited by the applicant in the international application</p> <p>“E” earlier application or patent but published on or after the international filing date</p> <p>“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>“O” document referring to an oral disclosure, use, exhibition or other means</p> <p>“P” document published prior to the international filing date but later than the priority date claimed</p> <p>“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>“&” document member of the same patent family</p>		
Date of the actual completion of the international search 27 July 2021		Date of mailing of the international search report 28 July 2021
Name and mailing address of the ISA/KR Korean Intellectual Property Office 189 Cheongsa-ro, Seo-gu, Daejeon 35208, Republic of Korea Facsimile No. +82-42-481-8578		Authorized officer Jung, Da Won Telephone No. +82-42-481-5373

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2021/026147

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2015-0307885 A1 (STRIKE BIO, INC. et al.) 29 October 2015 (2015-10-29) the whole document	1-4,13-15,28-31,33-37
A	WO 2010-115206 A2 (DICERNA PHARMACEUTICALS, INC.) 07 October 2010 (2010-10-07) the whole document	1-4,13-15,28-31,33-37

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. forming part of the international application as filed:
 - in the form of an Annex C/ST.25 text file.
 - on paper or in the form of an image file.
 - b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. furnished subsequent to the international filing date for the purposes of international search only:
 - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **45-46**
because they relate to subject matter not required to be searched by this Authority, namely:

Claims 45-46 pertain to a method for treatment of the human body by surgery or therapy(PCT Article 17(2)(a)(i) and Rule 39.1(iv)).
2. Claims Nos.: **6, 8, 10-11, 17, 19, 21-22, 24, 27, 42, 46**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 6, 8, 10-11, 17, 19, 21-22, 24, 27, 42, 46 are regarded to be unclear because they refer to claims which do not comply with PCT Rule 6.4(a).
3. Claims Nos.: **5, 7, 9, 12, 16, 18, 20, 23, 25-26, 32, 38-41, 43-45**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US2021/026147

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
US	2010-0286241	A1	11 November 2010	EP	2190995	A2	02 June 2010
				JP	2010-538678	A	16 December 2010
				WO	2009-108217	A2	03 September 2009
				WO	2009-108217	A3	21 January 2010
US	2015-0238515	A1	27 August 2015	CN	104583406	A	29 April 2015
				CN	109481455	A	19 March 2019
				EP	2844757	A2	11 March 2015
				EP	3272868	A1	24 January 2018
				EP	3736333	A1	11 November 2020
				JP	2015-517466	A	22 June 2015
				KR	10-2015-0004414	A	12 January 2015
				US	2018-0153919	A1	07 June 2018
				WO	2013-166004	A2	07 November 2013
				WO	2013-166004	A3	03 January 2014
US	2019-0055562	A1	21 February 2019	EP	3405576	A1	28 November 2018
				US	10619159	B2	14 April 2020
				US	2020-0248185	A1	06 August 2020
				WO	2017-127473	A1	27 July 2017
US	2015-0307885	A1	29 October 2015	CN	106661576	A	10 May 2017
				EP	3134528	A1	01 March 2017
				JP	2017-518764	A	13 July 2017
				US	9683237	B2	20 June 2017
				WO	2015-164818	A1	29 October 2015
WO	2010-115206	A2	07 October 2010	CN	102325534	A	18 January 2012
				CN	102325534	B	17 February 2016
				CN	102497870	A	13 June 2012
				CN	102575254	A	11 July 2012
				CN	102575254	B	04 March 2015
				CN	102753187	A	24 October 2012
				CN	103555722	A	05 February 2014
				CN	103555722	B	31 August 2016
				CN	104651362	A	27 May 2015
				CN	105907756	A	31 August 2016
				EP	2341943	A2	13 July 2011
				EP	2341943	B1	07 November 2018
				EP	2379083	A2	26 October 2011
				EP	2379083	B1	16 August 2017
				EP	2414374	A2	08 February 2012
				EP	2437751	A2	11 April 2012
				EP	2437752	A2	11 April 2012
				EP	2513334	A1	24 October 2012
				EP	2513334	B1	14 November 2018
				EP	2756845	A1	23 July 2014
				EP	2756845	B1	15 March 2017
				EP	3199165	A1	02 August 2017
				ES	2628144	T3	01 August 2017
				ES	2708944	T3	12 April 2019
				JP	2012-504389	A	23 February 2012
				JP	2012-512651	A	07 June 2012

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US2021/026147

Patent document cited in search report	Publication date (day/month/year)	Patent family member(s)	Publication date (day/month/year)
		JP 2012-528596 A	15 November 2012
		JP 2012-528882 A	15 November 2012
		JP 2012-531888 A	13 December 2012
		JP 2013-514089 A	25 April 2013
		JP 2015-198657 A	12 November 2015
		JP 2015-213512 A	03 December 2015
		JP 2015-221042 A	10 December 2015
		JP 2017-079761 A	18 May 2017
		JP 5855463 B2	09 February 2016
		JP 5986928 B2	06 September 2016
		JP 6010458 B2	19 October 2016
		JP 6295232 B2	14 March 2018
		KR 10-1728655 B1	19 April 2017
		KR 10-1791702 B1	30 October 2017
		KR 10-2011-0110776 A	07 October 2011
		KR 10-2012-0034610 A	12 April 2012
		KR 10-2016-0118377 A	11 October 2016
		US 10131912 B2	20 November 2018
		US 10752899 B2	25 August 2020
		US 10837013 B2	17 November 2020
		US 10870849 B2	22 December 2020
		US 2010-0173973 A1	08 July 2010
		US 2010-0173974 A1	08 July 2010
		US 2010-0184841 A1	22 July 2010
		US 2010-0249214 A1	30 September 2010
		US 2010-0331389 A1	30 December 2010
		US 2011-0003881 A1	06 January 2011
		US 2011-0021604 A1	27 January 2011
		US 2011-0059187 A1	10 March 2011
		US 2011-0111056 A1	12 May 2011
		US 2011-0288147 A1	24 November 2011
		US 2012-0095200 A1	19 April 2012
		US 2012-0263738 A1	18 October 2012
		US 2013-0041010 A1	14 February 2013
		US 2013-0096290 A1	18 April 2013
		US 2013-0123342 A1	16 May 2013
		US 2013-0225663 A1	29 August 2013
		US 2014-0221454 A1	07 August 2014
		US 2014-0350074 A1	27 November 2014
		US 2015-0038554 A1	05 February 2015
		US 2015-0038555 A1	05 February 2015
		US 2015-0057337 A1	26 February 2015
		US 2018-0044680 A1	15 February 2018
		US 2020-0318118 A1	08 October 2020
		US 8349809 B2	08 January 2013
		US 8372816 B2	12 February 2013
		US 8513207 B2	20 August 2013
		US 8927705 B2	06 January 2015
		US 9200284 B2	01 December 2015
		US 9320798 B2	26 April 2016

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US2021/026147

Patent document cited in search report	Publication date (day/month/year)	Patent family member(s)	Publication date (day/month/year)
		US 9809819 B2	07 November 2017
		WO 2010-033225 A2	25 March 2010
		WO 2010-033225 A3	05 January 2012
		WO 2010-080129 A2	15 July 2010
		WO 2010-080129 A3	16 September 2010
		WO 2010-093788 A2	19 August 2010
		WO 2010-093788 A3	07 October 2010
		WO 2010-115202 A2	07 October 2010
		WO 2010-115202 A3	09 December 2010
		WO 2010-115206 A3	25 November 2010
		WO 2010-141724 A2	09 December 2010
		WO 2010-141724 A3	03 February 2011
		WO 2010-141726 A2	09 December 2010
		WO 2010-141726 A3	27 January 2011
		WO 2010-141933 A1	09 December 2010
		WO 2011-072292 A2	16 June 2011
		WO 2011-072292 A3	29 September 2011
		WO 2011-075188 A1	23 June 2011
		WO 2011-109294 A1	09 September 2011
